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1 Abstract
Coronavirus Disease 2019 (COVID-19) is an emerging respiratory disease caused
by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with
rapid human-to-human transmission and a high case fatality rate particularly in
older patients. Due to the exponential growth of infections, many healthcare
systems across the world are under pressure to care for increasing amounts of
at-risk patients. Given the high number of infected patients, identifying patients
with the highest mortality risk early is critical to enable effective intervention and
optimal prioritisation of care. Here, we present the COVID-19 Early Warning
System (CovEWS), a clinical risk scoring system for assessing COVID-19 related
mortality risk. CovEWS provides continuous real-time risk scores for individual
patients with clinically meaningful predictive performance up to 192 hours (8
days) in advance, and is automatically derived from patients’ electronic health
records (EHRs) using machine learning. We trained and evaluated CovEWS
using de-identified data from a cohort of 66 430 COVID-19 positive patients
seen at over 69 healthcare institutions in the United States (US), Australia,
Malaysia and India amounting to an aggregated total of over 2 863 years of
patient observation time. On an external test cohort of 5 005 patients, CovEWS
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predicts COVID-19 related mortality from 78.8% (95% confidence interval [CI]:
76.0, 84.7%) to 69.4% (95% CI: 57.6, 75.2%) specificity at a sensitivity greater
than 95% between respectively 1 and 192 hours prior to observed mortality events
- significantly outperforming existing generic and COVID-19 specific clinical risk
scores. CovEWS could enable clinicians to intervene at an earlier stage, and
may therefore help in preventing or mitigating COVID-19 related mortality.
2 Introduction
The coronavirus disease 2019 (COVID-19) pandemic has recently emerged as a
major and urgent threat to healthcare systems worldwide. Since early reports
of its outbreak in China in December 2019, the number of global cases has
risen to over 21 million known infections and resulted in over 750 000 deaths
worldwide as of August 16, 2020 [1]. Despite public health efforts aimed at
improving testing [2], developing potential vaccines [3], and improving prevention
strategies [4], the disease is placing a significant burden on healthcare systems and
existing resources in many countries, particularly where its spread has not been
mitigated. Efficient early detection of patients likely to develop critical illness is
thus crucial to optimise the allocation of limited resources, and monitor overall
disease progression [5, 6]. The use of clinical predictive models from electronic
health records (EHRs) can help reduce some of this burden and inform better
decisions overall [7, 8, 9, 10]. For instance, a model able to predict in advance
which patients are at higher risk of mortality may help ensure resources are
prioritized accordingly for these individuals. In addition, as more observational
data are gathered, these models could be used both to discover new risk factors
as well as reveal interactions between existing factors, offering better insights
and opportunities for appropriate intervention.
Several approaches have been proposed to determine potential risk factors
that contribute to COVID-19 mortality. Some of these approaches identify
demographics and inflammatory markers associated with increased mortality
[11, 12], but do not account for risk factors potentially changing over time.
Moreover, many existing analyses are limited to a single source of data, often
from a single hospital, for both learning a model and predicting a patient’s
risk which may limit the generalisability of these analyses [13]. Other more
traditional measures of patient prognosis such as Sequential Organ Failure
Assessment (SOFA) scores [14] are based on examining a fixed set of risk factors
not specifically adapted to COVID-19; such measures fail to account for relevant
changes in patient status outside these risk factors, and therefore often do not
reach high levels of sensitivity and specificity in identifying high-risk patients.
Due to these challenges, to date, there does not yet exist a COVID-19 risk
score that (i) makes use of multiple, representative sources of data to account
for patient heterogeneity, (ii) includes important short-term and long-term risk
factors that have a significant impact on mortality risk, (iii) reacts in real time
to potentially rapid changes in patient status, and (iv) is adapted to risk factors
relevant to COVID-19.
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To address these issues, we developed the COVID-19 Early Warning System
(CovEWS), a risk assessment system for real-time prediction of COVID-19-
related mortality that we trained on a large and representative sample of EHRs
collected from more than 69 healthcare institutions using machine learning. In
contrast to existing risk scores, CovEWS provides early warnings with clinically
meaningful predictive performance up to 192 hours prior to observed mortality
events, hence enabling critical time to intervene to potentially prevent such events
from occurring. Since CovEWS is automatically derived from patient EHRs, it
updates in real time without any necessity for manual action to reflect changes in
patient status, and accounts for a much larger number of risk factors correlated
with COVID-19 mortality than existing risk scores. CovEWS is based on a
time-varying neural Cox model that accounts for risk factors changing over time
and potential non-linear interactions between risk factors and COVID-19-related
mortality risk1, and was derived from the de-identified EHRs of 66 430 diverse
COVID-19 positive patients. We demonstrate experimentally that the predictive
performance of CovEWS is superior to existing generic risk scores, such as SOFA
[14], COVID-19 specific risk scores, such as the machine learning models from
Yan et al. [17] and Liang et al. [18], and COVER F [19], and a time-varying
Cox model with linear interactions [20]. We additionally show that the gradient
information of our differentiable CovEWS model can be used to quantify the
influence of the input risk factors on the output score in real time. CovEWS
may enable clinicians to identify high-risk patients at an early stage, and may,
therefore, help improve patient outcomes through earlier intervention.
3 Results
COVID-19 Early Warning System (CovEWS). CovEWS is a clinical
mortality risk prediction system for COVID-19 positive patients to be used in
a continuous manner in both inpatient and outpatient settings. CovEWS uses
clinical risk factors from a patient’s EHR to automatically calculate a mortality
risk score between 0 and 100 that indicates the current risk percentile that this
patient is in relative to the reference cohort2. A CovEWS score of 90 indicates,
for example, that the patient has a higher COVID-19 related mortality risk
than 90% of COVID-19 positive patients in the reference cohort. An important
property of CovEWS scores is that they always reflect the momentary risk
of patients in their current states, and that they update instantaneously to
reflect relevant, EHR-derived changes, which is a key differentiator of CovEWS
compared to existing COVID-19 related mortality risk prediction systems that
are not designed to take into account new, incoming clinical evidence. Figure 1
demonstrates the application of CovEWS to two contrasting patient timelines (a
deteriorating patient that ultimately died and a patient that initially deteriorates
but then recovers) by visualising a selected number of clinical risk factors,
1While these extensions have been pursued in [15] and [16] separately, they have neither
been considered in combination nor in the context of COVID-19 risk scoring using EHRs.
2See Section S.6 for a mathematical definition of CovEWS.
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(a) Patient A
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(b) Patient B
Figure 1: A selected number of clinical risk factors, corresponding Sequential
Organ Failure Assessment (SOFA) scores, and COVID-19 Early Warning Sys-
tem (CovEWS) scores for two contrasting patient timelines. Positive (red) and
negative (blue) importance contributions (coloured areas above the clinical time
series, see Section S.11) indicate to what degree the risk factor at that time
point contributed to increasing or decreasing to the mortality risk predicted
by CovEWS, respectively. Patient A’s (left) oxygen saturation (SPO2) fluctu-
ates significantly before dropping below 95% after around 150 hours since her
COVID-19 diagnosis, suggesting respiratory distress. The patient is subsequently
intubated. This is followed by a sharp rise in serum creatinine levels, indicating
potential acute kidney injury. Both SOFA and CovEWS reflect these events
with an increase in Patient A’s risk. Crucially, however, since CovEWS accounts
for early deterioration in SPO2 and white blood cell counts, it identifies the
patient as high-risk much sooner than SOFA, triggering re-evaluation of current
treatment strategy, including investigation for delayed complication or treatment
injury, and/or the initiation of goals of care discussion. In Patient B (right),
different risk factors, including c-reactive protein (CRP), respiratory rate (RR)
and SPO2, weigh heavily in risk assessment. Initially, Patient B’s RR increases
significantly to over 30 breaths per minute while her SPO2 drops below 95%,
reflected by a corresponding increase in both SOFA and CovEWS. Patient B’s
RR and CRP levels however stabilise, which is correctly reflected in a lowering
of the mortality risk by CovEWS. Intubation is averted for this patient. In
contrast, SOFA does not account for the improvements in SPO2, RR and does
not reflect Patient B’s now improved state.
4 September 1, 2020
such as respiratory rate, oxygen saturation, and creatinine levels, alongside the
corresponding momentary risk assessment output by CovEWS. As shown in
Figure 1, CovEWS additionally maintains a high degree of interpretability for
clinicians by indicating the relative positive and negative influences of each
clinical risk factor over time on the predicted risk score (see Section S.11). The
information conveyed by CovEWS can be used to quickly and objectively assess
individual COVID-19 related mortality risk in order to prevent or mitigate
mortality, and optimise prioritisation of scarce healthcare resources.
To develop CovEWS, we used EHR data from two federated networks of US
and international healthcare organisations (HCOs), Optum (US) and TriNetX
(US + international), that include de-identified EHRs containing data on demo-
graphics, clinical measurements, vital signs, lab tests and diagnoses of 47 384
and 5 005 patients seen between March 21st and June 5th 2020 (11 weeks) and
March 21st and June 25st 2020 (13 weeks), respectively. To demonstrate the
generalisability of predictions made by CovEWS, we limited the training of Cov-
EWS to a training cohort of 14 215 (30%) patients from the Optum cohort, used
9 477 (20%) Optum patients for model selection, and evaluated CovEWS against
both a held-out test cohort of 14 215 (30%) patients from the Optum cohort and
a separate external test cohort consisting of the entire TriNetX cohort of 5 005
(100%) patients (Table 1, stratification details in Section S.4). In addition, we
collected supplementary EHR data on new patients diagnosed with COVID-19
between June 6th to July 13th 2020 (5 weeks) from Optum - the Optum future
cohort (14 041 patients) - after CovEWS had been trained to demonstrate the
robustness of CovEWS under rapidly changing treatment regimes3 and other
temporal effects. The data formats were normalised across the two federated
networks of HCOs (Section S.3), and all data were preprocessed to address the
missingness that is characteristic for real-world clinical data (Section S.5).
Predictive Performance for Different Prediction Horizons. We com-
pared the predictive performance of CovEWS, several baselines and existing risk
prediction scores (Section S.12), including a version of CovEWS based on a linear
time-varying Cox model [20] (CovEWS [linear], Section S.6.3), COVID-19 Esti-
mated Risk for Fatality (COVER F) [19], Sequential Organ Failure Assessment
(SOFA) [14], the decision tree developed by Yan et al. [17] and the deep learning
model developed by Liang et al. [18], in terms of their respective specificity for
identifying COVID-19 related mortality with a conservative fixed sensitivity of
at least 95% and a slightly more relaxed level of 90% at a minimum of 1, 2, 4, 8,
16, 24, 48, 96 and 192 hours (8 days) prior to observed mortality events4 on both
the hold-out test data of Optum cohort and the external test cohort from the
TriNetX network (Figure 2). In terms of specificity at a sensitivity greater than
3During this period, the RECOVERY Collaborative Group reported results of randomised
clinical trials demonstrating the lack of efficacy of hydroxychloroquine [21] and the efficacy
of dexamethasone [22] in COVID-19 patients on June 5th 2020 and June 16th, respectively -
which significantly impacted clinical treatment practice of COVID-19 patients.
4The last observed EHR entry’s date was taken as a reference time for those patients that
did not have an observed mortality event during the data collection period.
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Figure 2: Performance comparison in terms of Specificity at greater than either
95% or 90% Sensitivity (y-axis) for different prediction horizons ahead of observed
mortality events (in hours, x-axis) for CovEWS, CovEWS (linear), COVID-
19 Estimated Risk for Fatality (COVER F) [19], Sequential Organ Failure
Assessment (SOFA) [14], Liang et al. [18], and Yan et al. [17] on the held-out
Optum test set, the external TriNetX test set, and selected patient subgroups
from the Optum test set. Some methods do not reach 90% and 95% sensitivity
for some horizons, and may therefore not be visible in all plots. Bars indicate
median and error bars indicate 95% confidence intervals (CIs) obtained via
bootstrapping with 200 samples. Detailled results are available in Section S.15.
(* = p < 0.10, ** = p < 0.05, *** = p < 0.01, NS = not significant, one-sided
Mann-Whitney-Wilcoxon for superiority of CovEWS over CovEWS [linear]).
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95%, we found that CovEWS significantly (p < 0.05, one-sided Mann-Whitney-
Wilcoxon with Bonferroni correction, see Table S9 and Table S10) outperformed
other baselines and existing risk prediction scores at each prediction horizon and
on both the Optum and TriNetX cohorts with few exceptions. By comparing the
predictive performances of the mortality prediction scores at different time hori-
zons, we additionally quantified the degree to which risk prediction methods give
more accurate predictions when the mortality event is closer to the prediction
date. For example, the predictive performance of CovEWS in terms of specificity
at a sensitivity greater than 95% dropped from 89.3% (95% confidence interval
[CI]: 83.0, 91.6%) to 70.5% (95% CI: 65.6, 76.4%) and from 78.8% (95% CI: 76.0,
84.7%) to 69.4% (95% CI: 57.6, 75.2%) from 1 hour to 192 hours prior to an
observed mortality event on the held-out Optum test cohort and the external
TriNetX test cohort, respectively. When comparing the predictive performance
across the held-out Optum test cohort and the external TriNetX test cohort, we
saw the same trends in performance. However, all methods were roughly 10%
less specific at greater than 95% sensitivity. This difference persisted even in
those risk assessment systems that were not originally trained on the Optum
training cohort, such as COVER F. We thus attributed this apparent difference
in performance not to overfitting to the Optum training cohort, but to (i) the
difference of 5.38% against 6.91% in baseline mortality between the held-out
Optum test cohort and the external TriNetX test cohort, respectively, and (ii)
the higher degree of missingness in short-term mortality risk factors, such as, e.g.,
respiratory rate, SpO2 and blood pressure, in TriNetX (Table 1). In addition to
assessing predictive performance, we also evaluated the calibration [23] of the risk
scores predicted by CovEWS. We found that CovEWS overestimates mortality
risk when interpreted as the probability of a mortality event occurring within
the next 24 hours because patients’ states may change between the prediction
time and the end of the prediction horizon (Figure S7).
Predictive Performance for Different Subgroups. We also compared the
predictive performance of CovEWS against the baselines and existing scores
across various ethnic subgroups, on patients that were not hospitalised, and on
the Optum future cohort (Figure 2; cohort statistics in Table 2). Overall, across
each of these cohorts, we found that CovEWS significantly (p < 0.05, one-sided
Mann-Whitney-Wilcoxon with Bonferroni correction) outperformed all of the
baselines at each prediction horizon with the sole exception being the 96 and 192
hours prediction horizons on the Optum future cohort - where the performance
difference was not in all cases significant. The performance difference was more
pronounced across Caucasian and African American populations which is likely
reflective of the fact that several baselines have been developed using data from
predominantly Asian populations. On the subgroup of patients that was not
hospitalised, we found that, although lower than the overall performance on the
entire Optum test set, CovEWS maintained a high level of performance. We
attributed the lower performance on the non-hospitalised group compared to the
overall Optum test set to (i) the considerably higher missingness in this patient
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group caused by non-hospitalised patients not being monitored as closely as
hospitalised patients (Table S6), and (ii) the overall considerably lower mortality
rate in this patient group. Respectable performance on the non-hospitalised
patient group is particularly important since the majority of COVID-19 patients
are treated in an outpatient setting. In addition, when evaluating the various
risk assessment methods on the Optum future cohort, we found that CovEWS
was largely robust to changes in treatment policies and other temporal effects.
A notable anomaly was the 96 and 192 hours prediction horizons where the
variance in our performance estimates was relatively high since fewer patients
with recorded mortality outcomes and long-term monitoring data were available
due to the shorter data collection time (5 weeks) of the Optum future cohort
compared to the Optum test set (11 weeks) and the TriNetX test set (13 weeks).
Stratified Time-varying Survival Analysis. As illustrated in the examples
in Figure 1, CovEWS continuously varies over time since it accounts for the
status of patients deteriorating or improving. To add to the analysis of the
predictive performance of CovEWS in identifying the mortality of individual
patients at fixed prediction horizons prior to observed mortality events presented
in the previous paragraph, we therefore additionally evaluated whether CovEWS
enables stratification of high-risk patients continuously over time. To do so,
we stratified the held-out Optum test cohort and the external TriNetX cohort
into five strata of the CovEWS score respectively assigned to each patient
(Section 3). We found that CovEWS effectively separated patients into risk
groups with distinct COVID-19 related mortality risk profiles, as patients that
were assigned to higher strata of CovEWS scores were more likely to die across
all strata over the course of their disease. When comparing stratification results
between the held-out Optum test cohort and the external TriNetX cohort, we
observed that the ability to stratify patients into risk groups generalised across
the two datasets - indicating that the predictive performance of CovEWS can
transfer to other sources of data collected with different protocols, from different
locations, and under different treatment policies. We also observed that the
highest risk stratum of patients assigned CovEWS scores between 90 and 100 was
considerably steeper than other strata in the held-out Optum test cohort and
this anomaly did not persist to the same degree in the external TriNetX cohort.
Qualitatively, we reasoned that this difference between the two datasets was
due to the considerably higher missingness of short-term risk factors associated
with mortality, such as, e.g., respiratory rate, SpO2 and blood pressure, in
the TriNetX cohort (Table 1). Rapid changes in these short-term risk factors
often result in substantially increased near-term mortality risk and CovEWS
scores reflected this increased risk immediately (Figure 1), moving patients with
extreme short-term risk indicators into the highest risk stratum. Since these
short-term risk factors were not included as frequently in the TriNetX cohort,
CovEWS was considerably less able to react to short-term deteriorations in the
status of the patients, which was reflected in a relatively flatter time-varying
survival curve of the highest risk stratum in the TriNetX cohort.
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Figure 3: Stratification of patients in the held-out Optum test cohort (left) and
the external TriNetX test cohort according to their assigned CovEWS score over
time (in hours since COVID-19 diagnosis) into those patients that were assigned
a CovEWS score below 60, from 60 to 69, 70 to 79, 80 to 89, and 90 to 100 on
the test fold of the Optum dataset. Note that the five strata and their respective
limits were chosen for clarity of visualisation - other strata are possible, and
may, depending on context, have better clinical utility. Rows show time-varying
survival probabilities (top row), the number of patients (centre row), and the
cumulative number of mortality events observed (bottom row) for patients in
each stratum of assigned CovEWS scores. Steeper curves indicate that more
patients died while assigned a CovEWS score in the respective stratum. In
contrast to traditional survival curves, cohorts as defined by strata of CovEWS
scores are not static over time, and patients move between the stratified groups
as they are assigned lower or higher CovEWS scores in response to their status
improving or deteriorating, respectively. The results showed that CovEWS
enables effective stratification of patients into risk groups over the course of their
disease, as patients that were assigned a higher CovEWS score were more likely
to die over time on both test cohorts while maintaining separation between the
stratified cohorts.
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Table 1: Descriptive statistics and percentage of patients with missing entries (Miss. %) for the training, validation and test sets
of the Optum cohort and the external TriNetX test cohort. Input covariates of CovEWS are placed towards the bottom of the
table and separated from covariates that are not inputs by a horizontal line. For binary covariates, the Value columns indicate
the percentage of patients presenting with the condition at the end of their respective observation periods. For continuous
measurements, the Value columns indicate the median and 10th and 90th percentiles in parentheses of the observed value for
measurements that are collected once per patient, such as age, and the median of observed values for measurements that are
collected multiple times per patient, such as heart rate. Table S5 presents the ICD codes corresponding to the shown diagnoses.
BMI = Body Mass Index, HIV = Human Immunodeficiency Virus, COPD = Chronic Obstructive Pulmonary Disease, GGT =
Gamma Glutamyl Transferase, AAT = Aspartate Aminotransferase, IL6 = Interleukin 6, n/a = not available.
M
o
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l
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n
p
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t
s
Optum TriNetX
March 21 - June 5 2020 March 21 - June 25 2020
Training Set Validation Set Test Set External Test Set
Value Miss.% Value Miss.% Value Miss.% Value Miss.%
Patients [#] 23 692 - 9 477 - 14 215 - 5 005 -
COVID-19 [%] 100.00 - 100.00 - 100.00 - 100.00 -
Hispanic [%] 11.90 - 11.44 - 12.18 - 5.57 -
Black [%] 23.33 - 23.94 - 23.30 - 37.74 -
Caucasian [%] 50.19 - 49.67 - 49.31 - 40.28 -
Asian [%] 3.41 - 3.43 - 3.61 - 3.30 -
Inpatient admission [%] 32.16 - 33.06 - 32.24 - n/a 100.00
ICU admission [%] 7.12 - 7.13 - 7.13 - n/a 100.00
Mortality [%] 5.34 - 5.38 - 5.38 - 6.91 -
Female [%] 54.14 0.04 54.16 0.03 54.15 0.04 53.67 -
Age [years] 54.00 (27.00, 80.00) - 54.00 (27.00, 80.00) - 54.00 (27.00, 80.00) - 55.00 (30.00, 78.00) -
Weight [kg] 82.97 (58.97, 117.93) 42.90 82.81 (58.23, 117.93) 42.11 82.70 (58.94, 117.52) 42.48 n/a 100.00
Height [cm] 167.64 (154.94, 182.88) 47.27 167.64 (154.94, 182.88) 46.74 167.64 (154.94, 182.88) 46.68 n/a 100.00
BMI [kg/m2] 29.32 (22.05, 40.64) 46.13 29.32 (21.95, 40.71) 45.65 29.26 (22.02, 40.74) 45.64 28.19 (19.35, 36.57) 79.02
Intubation [%] 4.23 - 4.22 - 4.24 - 9.53 -
Temperature [°C] 36.90 (36.45, 37.61) 37.75 36.90 (36.43, 37.63) 36.56 36.90 (36.46, 37.63) 37.50 36.94 (36.28, 37.56) 84.06
SpO2 [%] 96.33 (93.38, 99.00) 35.50 96.33 (93.32, 99.00) 34.45 96.29 (93.38, 99.00) 35.26 95.00 (90.71, 98.00) 82.44
Heart rate [/min] 84.33 (68.89, 102.67) 38.14 84.36 (68.29, 102.17) 37.04 84.70 (68.80, 102.93) 37.46 84.56 (66.48, 103.00) 79.82
Respiratory rate [/min] 18.59 (16.00, 24.00) 42.74 18.57 (16.00, 24.00) 41.87 18.67 (16.00, 24.00) 42.21 18.50 (16.00, 24.93) 75.42
Dyspnea [%] 57.07 - 57.55 - 56.38 - 48.09 -
Sys. blood pressure [mmHg] 125.16 (108.22, 146.96) 39.24 125.21 (108.69, 146.76) 38.42 125.00 (108.31, 146.43) 38.56 126.00 (107.00, 148.00) 42.12
Dias. blood pressure [mmHg] 73.38 (61.67, 87.00) 39.27 73.58 (61.69, 87.26) 38.39 73.60 (61.69, 87.03) 38.58 73.50 (60.10, 87.00) 42.12
Kidney disease [%] 13.13 - 13.13 - 13.42 - 14.53 -
Ischemic heart disease [%] 18.71 - 19.62 - 18.07 - 15.26 -
Other heart diseases [%] 53.55 - 54.01 - 54.06 - 56.36 -
Cerebovascular disease [%] 10.43 - 10.93 - 10.63 - 10.51 -
Hypertension [%] 46.10 - 45.85 - 46.16 - 48.37 -
Diabetes [%] 25.03 - 24.69 - 24.84 - 28.45 -
Hyperlipidemia [%] 40.25 - 40.53 - 40.56 - 38.26 -
Cancer [%] 21.48 - 20.92 - 21.41 - 21.80 -
COPD [%] 9.23 - 9.13 - 8.79 - 8.31 -
Asthma [%] 15.32 - 14.77 - 15.16 - 16.62 -
Pulmonary embolism [%] 2.98 - 3.01 - 2.69 - 3.66 -
Connective tissue disease [%] 2.56 - 2.73 - 2.72 - 4.38 -
Inflamatory bowel disease [%] 1.44 - 1.33 - 1.36 - 1.20 -
Osteoarthritis [%] 21.73 - 22.27 - 22.44 - 18.02 -
Rheumatroid arthritis [%] 27.59 - 29.01 - 27.81 - 21.14 -
HIV [%] 0.60 - 0.65 - 0.64 - 0.90 -
Smoking (never) 44.02 36.18 44.71 34.77 44.16 36.46 0.00 100.00
Smoking (previous) 15.48 36.18 16.44 34.77 15.15 36.46 0.00 100.00
Smoking (current) 4.32 36.18 4.08 34.77 4.22 36.46 0.00 100.00
Smoking (unknown) 0.00 36.18 0.00 34.77 0.00 36.46 0.00 100.00
White blood cells [10*3/ul] 6.94 (4.17, 12.34) 49.24 6.96 (4.16, 12.26) 48.57 6.98 (4.18, 12.45) 48.40 7.12 (4.46, 13.08) 96.72
Neutrophil [%] 70.50 (51.89, 84.25) 50.67 71.00 (51.40, 84.65) 50.08 70.98 (52.33, 84.43) 49.87 72.10 (54.65, 85.48) 97.16
Lymphocytes [%] 18.28 (7.50, 35.40) 50.66 18.00 (7.20, 35.70) 50.05 18.02 (7.50, 35.00) 49.84 13.01 (5.28, 28.53) 91.13
Eosinophil [%] 0.75 (0.00, 3.00) 51.41 0.70 (0.00, 3.00) 51.00 0.73 (0.00, 2.97) 50.57 1.45 (0.15, 3.96) 92.71
Basophil [%] 0.30 (0.00, 1.00) 51.48 0.30 (0.00, 1.00) 51.06 0.28 (0.00, 0.91) 50.70 0.36 (0.10, 1.35) 91.37
Platelets [10*3/ul] 232.38 (143.00, 365.00) 49.28 233.21 (144.00, 368.10) 48.62 232.68 (144.00, 366.63) 48.45 220.09 (141.55, 345.90) 96.76
C-reactive protein [mg/l] 73.62 (8.00, 185.52) 68.39 71.50 (8.98, 184.92) 67.98 73.38 (9.00, 183.01) 67.81 69.29 (6.00, 200.12) 55.18
hs. C-reactive protein [mg/l] 56.55 (4.85, 162.00) 96.62 61.10 (3.43, 168.00) 96.66 56.14 (4.96, 158.78) 96.31 16.19 (3.38, 167.23) 99.28
Procalcitonin [ng/ml] 0.16 (0.04, 2.59) 82.33 0.16 (0.04, 2.82) 81.96 0.17 (0.04, 2.59) 81.99 0.24 (0.06, 3.08) 79.98
Fibrin D-dimer [mg/l] 0.91 (0.29, 4.95) 93.20 0.95 (0.31, 5.83) 93.15 0.89 (0.26, 4.72) 93.16 0.00 (0.00, 0.01) 88.63
Ferritin [ng/ml] 574.00 (97.34, 2196.90) 69.77 567.85 (101.02, 2211.85) 69.59 566.49 (96.00, 2212.00) 69.13 798.00 (155.52, 5625.30) 62.10
Cardiac Troponin T [ng/ml] 0.02 (0.00, 0.15) 69.57 0.02 (0.00, 0.18) 68.94 0.02 (0.00, 0.16) 69.05 0.01 (0.01, 0.09) 88.57
Creatinine [mg/dl] 0.91 (0.62, 2.14) 49.52 0.90 (0.61, 2.16) 48.65 0.90 (0.60, 2.13) 48.42 0.94 (0.62, 2.81) 40.48
Lactate dehydrogenase [U/l] 331.33 (191.00, 606.87) 70.94 335.00 (189.00, 605.71) 70.94 330.94 (193.45, 590.83) 70.55 348.00 (208.00, 703.67) 61.22
GGT [U/l] 54.50 (13.25, 280.90) 96.62 47.50 (13.30, 243.20) 96.55 54.50 (14.57, 318.00) 96.69 97.50 (20.80, 644.10) 99.32
AAT [U/l] 33.67 (17.00, 85.00) 54.60 34.00 (18.00, 88.39) 53.87 33.67 (17.27, 87.40) 53.77 39.15 (19.41, 96.38) 47.33
Creatine kinase [U/l] 124.81 (38.00, 660.14) 78.95 124.04 (37.00, 803.53) 78.61 126.00 (37.00, 722.20) 78.24 148.00 (37.49, 884.45) 81.62
Bilirubin [mg/dl] 0.50 (0.30, 1.00) 54.59 0.50 (0.30, 1.00) 53.84 0.50 (0.30, 1.00) 53.65 0.50 (0.30, 1.06) 46.65
Albumin [g/dl] 3.42 (2.50, 4.40) 54.41 3.42 (2.50, 4.40) 53.70 3.44 (2.50, 4.40) 53.48 3.27 (2.15, 4.20) 62.60
IL-6 [pg/ml] 24.42 (6.57, 168.48) 95.53 23.00 (7.00, 145.60) 95.60 24.33 (7.00, 171.30) 95.50 48.62 (8.86, 526.97) 87.77
pH 7.40 (7.28, 7.47) 84.29 7.40 (7.28, 7.47) 85.07 7.40 (7.28, 7.47) 84.29 7.41 (7.33, 7.47) 86.77
PCO2 [mmHg] 40.91 (31.00, 56.21) 88.03 41.00 (31.00, 55.93) 88.34 41.06 (30.37, 56.00) 88.05 40.36 (31.35, 51.01) 90.85
PaO2 [mmHg] 88.26 (61.00, 131.00) 88.08 87.18 (59.00, 127.26) 88.35 88.00 (60.00, 130.91) 88.10 86.23 (61.00, 135.97) 91.35
HCO3 [mmol/l] 25.00 (19.50, 30.21) 78.57 25.00 (19.60, 30.00) 79.04 25.00 (19.88, 30.00) 78.22 25.11 (20.03, 30.66) 80.98
CO2 [mmol/l] 24.50 (20.50, 28.33) 51.10 24.44 (20.50, 28.19) 49.95 24.40 (20.56, 28.33) 49.98 24.25 (20.51, 28.40) 58.08
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Table 2: Descriptive statistics for selected subgroups (Caucasian, Asian, Black or African American, Hispanic, Not Hospitalised)
of the held-out Optum test cohort, and for the Optum future cohort. Input covariates of CovEWS are placed towards the
bottom of the table and separated from covariates that are not inputs by a horizontal line. For binary covariates, the Value
columns indicate the percentage of patients presenting with the condition at the end of their respective observation periods. For
continuous measurements, the Value columns indicate the median and 10th and 90th percentiles in parentheses of the observed
value for measurements that are collected once per patient, such as age, and the median of observed values for measurements that
are collected multiple times per patient, such as heart rate. BMI = Body Mass Index, HIV = Human Immunodeficiency Virus,
COPD = Chronic Obstructive Pulmonary Disease, GGT = Gamma Glutamyl Transferase, AAT = Aspartate Aminotransferase,
IL6 = Interleukin 6, n/a = not available, † = see Section S.2 for an explanation of the non-zero intubation rate.
M
o
d
e
l
I
n
p
u
t
s
Held-out Optum Test Set Future Cohort
Black Hispanic Asian Caucasian Not Hospitalised June 6 - July 13 2020
Value Value Value Value Value Value
Patients [#] 3 312 1 732 513 7 010 9 366 14 041
COVID-19 [%] 100.00 100.00 100.00 100.00 100.00 100.00
Hispanic [%] 2.48 100.00 2.92 7.89 10.09 15.53
Black [%] 100.00 4.73 0.00 0.00 20.93 18.97
Caucasian [%] 0.00 31.93 0.00 100.00 51.70 49.47
Asian [%] 0.00 0.87 100.00 0.00 3.75 2.90
Inpatient admission [%] 36.78 44.69 31.19 29.60 0.00 24.44
ICU admission [%] 9.87 6.87 5.07 7.02 0.00 3.64
Mortality [%] 5.10 3.06 4.87 6.36 2.65 0.80
Female [%] 60.27 51.79 54.00 53.88 56.54 54.83
Age [years] 52.00 (28.00, 76.00) 45.00 (22.00, 70.00) 48.00 (28.00, 74.00) 58.00 (29.00, 84.00) 52.00 (27.00, 79.00) 44.00 (20.00, 73.00)
Weight [kg] 89.45 (63.50, 125.35) 79.78 (56.76, 108.86) 68.04 (52.64, 93.31) 82.78 (58.21, 117.52) 82.37 (58.61, 117.03) 81.40 (56.70, 115.18)
Height [cm] 168.91 (157.48, 183.00) 165.10 (152.40, 177.80) 162.56 (152.40, 175.26) 167.64 (154.94, 182.88) 167.64 (154.94, 182.88) 167.64 (153.67, 182.88)
BMI [kg/m2] 31.40 (23.00, 43.66) 29.75 (22.88, 39.44) 26.16 (20.74, 32.21) 28.93 (21.81, 40.10) 29.12 (21.95, 40.39) 28.80 (21.52, 39.43)
Intubation [%] 5.01 3.23 5.85 4.15 †1.75 0.49
Temperature [°C] 36.94 (36.50, 37.65) 36.90 (36.45, 37.70) 36.90 (36.50, 37.80) 36.85 (36.40, 37.60) 36.90 (36.40, 37.62) 36.83 (36.40, 37.68)
SpO2 [%] 96.81 (94.00, 99.00) 97.00 (93.75, 99.00) 96.50 (93.06, 99.00) 96.00 (93.04, 98.59) 96.82 (93.45, 99.00) 97.52 (94.61, 99.14)
Heart rate [/min] 85.86 (70.32, 103.33) 86.14 (71.58, 106.17) 86.22 (70.10, 103.48) 83.00 (67.00, 101.00) 84.00 (68.00, 103.00) 81.82 (65.84, 101.00)
Respiratory rate [/min] 18.68 (16.00, 24.00) 18.57 (16.00, 24.16) 19.00 (16.00, 24.99) 18.63 (16.00, 23.70) 18.00 (16.00, 22.88) 17.79 (15.27, 21.00)
Dyspnea [%] 61.50 51.50 52.44 59.49 52.34 45.17
Sys. blood pressure [mmHg] 127.87 (111.57, 150.00) 124.18 (107.00, 145.84) 121.32 (103.58, 143.57) 124.67 (108.34, 145.26) 125.16 (108.00, 146.00) 124.60 (107.86, 146.23)
Dias. blood pressure [mmHg] 75.30 (63.36, 89.21) 74.02 (62.00, 87.33) 73.89 (61.02, 87.61) 72.38 (61.00, 86.00) 74.52 (62.00, 87.96) 75.33 (63.00, 88.22)
Kidney disease [%] 18.39 7.39 7.99 14.47 10.39 7.64
Ischemic heart disease [%] 18.75 10.10 13.84 21.97 14.33 13.14
Other heart diseases [%] 62.98 39.38 43.86 59.39 47.92 41.97
Cerebovascular disease [%] 11.35 5.31 7.99 13.27 8.58 7.63
Hypertension [%] 57.49 32.91 34.11 50.07 40.85 33.77
Diabetes [%] 33.24 23.27 22.81 23.79 20.71 18.07
Hyperlipidemia [%] 41.67 29.56 34.89 48.15 37.88 32.67
Cancer [%] 23.19 13.39 12.87 26.73 20.05 18.55
COPD [%] 9.09 4.16 2.73 11.57 6.74 5.70
Asthma [%] 19.72 14.67 10.33 15.82 13.40 13.27
Pulmonary embolism [%] 3.74 1.27 1.36 2.87 1.85 1.56
Connective tissue disease [%] 3.47 1.96 1.17 3.17 2.21 2.17
Inflamatory bowel disease [%] 1.00 0.40 0.58 2.00 1.33 1.18
Osteoarthritis [%] 25.39 12.18 10.92 27.92 20.51 17.41
Rheumatroid arthritis [%] 36.11 20.15 15.20 32.13 25.43 24.04
HIV [%] 1.03 0.81 0.19 0.46 0.49 0.48
Smoking (never) 46.23 56.12 53.22 40.30 38.11 53.28
Smoking (previous) 15.76 10.22 8.58 18.13 12.53 14.91
Smoking (current) 6.16 3.87 3.12 3.88 3.07 5.44
Smoking (unknown) 0.00 0.00 0.00 0.00 0.00 0.00
White blood cells [10*3/ul] 6.75 (3.95, 12.33) 6.93 (4.29, 12.25) 7.06 (4.52, 12.35) 7.00 (4.24, 12.28) 6.80 (4.17, 11.90) 6.60 (4.20, 11.00)
Neutrophil [%] 71.00 (50.50, 84.74) 70.36 (54.00, 83.62) 73.31 (54.24, 85.30) 71.00 (53.31, 84.05) 69.00 (50.60, 84.33) 63.50 (46.52, 80.50)
Lymphocytes [%] 18.05 (7.44, 37.02) 19.09 (8.17, 34.98) 17.00 (6.98, 35.06) 17.67 (7.41, 34.00) 19.45 (7.53, 36.80) 24.80 (10.50, 40.80)
Eosinophil [%] 0.49 (0.00, 2.40) 0.57 (0.00, 2.66) 0.70 (0.00, 2.25) 0.95 (0.00, 3.00) 0.90 (0.00, 3.20) 1.25 (0.00, 4.00)
Basophil [%] 0.30 (0.00, 1.00) 0.25 (0.00, 0.70) 0.18 (0.00, 0.70) 0.30 (0.00, 1.00) 0.31 (0.00, 1.00) 0.42 (0.00, 1.00)
Platelets [10*3/ul] 236.00 (148.38, 369.84) 236.00 (150.40, 368.80) 242.33 (143.58, 348.74) 229.00 (141.20, 352.53) 234.33 (144.00, 362.94) 235.42 (151.00, 343.00)
C-reactive protein [mg/l] 70.00 (11.29, 172.50) 69.62 (5.75, 188.17) 79.08 (21.48, 176.79) 73.83 (9.00, 183.42) 69.12 (6.00, 179.19) 40.10 (2.75, 158.30)
hs. C-reactive protein [mg/l] 56.90 (9.20, 125.00) 56.55 (3.07, 138.76) 60.42 (3.95, 167.75) 57.00 (4.50, 170.20) 52.45 (3.26, 144.39) 9.10 (0.80, 122.33)
Procalcitonin [ng/ml] 0.18 (0.04, 3.84) 0.15 (0.04, 2.84) 0.32 (0.04, 2.83) 0.16 (0.04, 1.90) 0.19 (0.04, 2.96) 0.13 (0.04, 1.38)
Fibrin D-dimer [mg/l] 1.14 (0.32, 7.28) 0.53 (0.18, 2.40) 0.57 (0.25, 3.28) 0.93 (0.29, 3.70) 0.72 (0.24, 3.91) 0.79 (0.31, 3.50)
Ferritin [ng/ml] 574.83 (113.85, 2446.07) 554.47 (88.00, 1956.78) 911.01 (152.40, 3397.40) 540.20 (90.23, 2015.77) 533.73 (78.25, 2046.47) 298.20 (33.38, 1577.72)
Cardiac Troponin T [ng/ml] 0.01 (0.00, 0.13) 0.01 (0.00, 0.09) 0.03 (0.00, 0.49) 0.02 (0.00, 0.19) 0.03 (0.01, 0.20) 0.01 (0.00, 0.09)
Creatinine [mg/dl] 1.01 (0.67, 2.90) 0.80 (0.53, 1.85) 0.87 (0.57, 2.02) 0.89 (0.61, 1.88) 0.90 (0.61, 1.88) 0.86 (0.60, 1.44)
Lactate dehydrogenase [U/l] 347.00 (209.28, 602.25) 325.18 (183.77, 616.27) 394.50 (217.40, 719.21) 312.00 (186.50, 558.85) 328.00 (189.96, 586.03) 282.71 (171.00, 567.93)
GGT [U/l] 40.67 (20.00, 287.43) 69.90 (25.00, 538.32) 73.02 (25.05, 392.52) 43.00 (11.00, 247.54) 58.00 (13.00, 315.43) 30.00 (10.25, 202.75)
AAT [U/l] 34.00 (18.00, 85.45) 36.42 (18.00, 88.82) 44.67 (22.07, 133.48) 31.33 (17.00, 81.94) 30.54 (17.00, 80.41) 24.00 (15.00, 56.30)
Creatine kinase [U/l] 171.35 (49.50, 908.83) 105.29 (40.00, 497.77) 133.20 (42.94, 643.30) 100.47 (31.23, 593.24) 127.00 (41.00, 641.50) 110.00 (36.00, 564.10)
Bilirubin [mg/dl] 0.50 (0.28, 1.00) 0.50 (0.30, 0.90) 0.58 (0.30, 1.05) 0.50 (0.30, 1.00) 0.50 (0.30, 1.00) 0.45 (0.20, 0.90)
Albumin [g/dl] 3.43 (2.56, 4.20) 3.50 (2.55, 4.40) 3.40 (2.30, 4.40) 3.43 (2.50, 4.50) 3.62 (2.70, 4.60) 4.10 (2.90, 4.70)
IL-6 [pg/ml] 19.00 (6.48, 178.40) 22.00 (6.00, 233.17) 31.00 (7.88, 206.45) 21.67 (7.00, 165.00) 28.00 (7.00, 207.53) 8.10 (4.20, 52.49)
pH 7.40 (7.29, 7.48) 7.40 (7.27, 7.47) 7.41 (7.25, 7.46) 7.40 (7.28, 7.48) 7.39 (7.26, 7.47) 7.42 (7.31, 7.48)
PCO2 [mmHg] 40.38 (29.63, 53.60) 41.73 (32.00, 56.99) 42.04 (32.32, 57.66) 41.40 (30.00, 55.91) 40.95 (30.00, 57.89) 37.00 (28.25, 50.64)
PaO2 [mmHg] 87.30 (61.06, 136.69) 87.47 (60.18, 126.00) 97.29 (66.18, 129.43) 86.64 (59.00, 130.00) 86.78 (60.07, 141.46) 77.00 (53.00, 130.50)
HCO3 [mmol/l] 25.00 (19.97, 29.70) 25.00 (20.00, 30.25) 24.62 (18.52, 29.20) 25.00 (20.00, 30.53) 25.00 (20.00, 29.48) 24.67 (19.30, 29.00)
CO2 [mmol/l] 24.20 (20.33, 28.26) 24.42 (20.87, 28.07) 24.00 (19.39, 27.04) 24.59 (20.86, 28.71) 24.50 (20.75, 28.50) 24.13 (21.00, 28.00)
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4 Discussion
We developed and validated CovEWS, a real-time early warning system for
predicting mortality of COVID-19 positive patients, using routinely collected
clinical measurements and laboratory results from EHRs. When compared
to competitive baselines, our method not only provides accurate mortality
predictions for each patient, but also provides a real-time early warning system of
up to 192 hours (8 days) prior to an observed mortality event for individuals, while
identifying clinically-relevant factors for predictive performance. These results
are sustained across various ethnic groups and cohorts. Notably, in comparison
to existing mortality risk scoring systems, our method achieves significantly
higher performance in terms of specificity at greater than 95% sensitivity across
all evaluated prediction time frames, and generalises well to data collected under
different treatment and data collection policies and environmental conditions.
The implications of providing such an early warning system are significant. The
provided risk assessment could potentially broadly aid in clinical decision-making
as well as in the prioritisation of care and resource allocation. More specifically,
CovEWS could enable clinicians to intensify monitoring and therefore initiate
treatments earlier in patients with a higher risk of mortality. Moreover, as an
additional information source, CovEWS could also help clinicians to decide when
to initiate palliative care to improve the quality of remaining life for patients with
this need. Additional studies investigating if and how CovEWS can influence
clinical decision-making would be necessary to improve both treatment outcomes,
the involvement of palliative care, or resource allocation to reduce COVID-related
mortality.
Before applying CovEWS in clinical practice, it is important to decide and
calibrate appropriate warning thresholds, e.g. at the 85%, 90% or 95% sensitivity
level (Section S.10). Especially when hospitals are overwhelmed and need to
strictly allocate resources, alarm fatigue due to ill-calibrated thresholds ought to
be minimised. In addition, while the data used in this study already comprises
multiple hospitals, a further analysis including hospitals from other countries
would be useful to investigate the impact of geographic and cultural differences
- particularly in those geographic contexts that are not well covered by this
study. Due to differences in data collection methodology and expected data
formats, another limitation of this study is that the implementation of some
existing risk scoring systems is based on certain assumptions that may adversely
influence their comparative performance (Section S.12). Moreover, this work
only concerns risk scores from routinely collected clinical data and patients
who are already seeking care at healthcare providers. For efficient mitigation of
COVID-19, additional, potentially preventative efforts like tracking apps, risk
scores of infection prior to admission, masks and social distancing are necessary.
It is also important to acknowledge upfront the pitfalls of mortality prediction
of hospitalised patients. A significant proportion of patients who die in the
hospital, do so after cessation of treatment. One may argue that models that
predict mortality thus actually predict the likelihood of treatment discontinuation.
Numerous factors go into the decision with regard to continuing or stopping
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interventions, including whether the outcome, if the patient were to survive,
is aligned with the patient’s preferences. It will only be accurate in a clinical
context where clinicians make predictions in a similar manner, where patients
share the same values and preferences around the quality of life, and where the
decision-making process resembles that of the training cohort.
From the perspective of medical staff, prognostication as well as the perception
of the quality of life if the patient were to survive, determine the framing of
patient status to the family and friends; these are vulnerable to bias, both
conscious or unconscious and influence the decision to admit the patient to the
intensive care unit, as well as the decision to discontinue treatment (which almost
certainly lead to death among those who are most severely ill). In a perfect world
without bias and health disparities, only patient and disease factors determine
hospital mortality, but studies have repeatedly demonstrated that this is far from
the case. Recently, mortality from critical illness has been shown to be higher in
disproportionately minority-serving hospitals after adjustment for illness severity
and other biological factors that pertain to the patient and to the disease [24, 25].
It is nearly impossible to incorporate these factors precisely in a model that
is trained on mortality as an outcome. As a decision support tool to inform
discussion around goals of care, CovEWS is subject to the same limitations that
mortality prediction models have – it may permeate or even magnify existing
health disparities and provider bias. As an early warning system, however,
we speculate that the impact of the exclusion of social determinants on model
performance is acceptable.
In summary, we presented, developed, and experimentally validated CovEWS,
a real-time early warning system that provides clinically meaningful predictions
of COVID-19 related mortality up to 192 hours (8 days) in advance for individual
patients using routinely collected EHR data. In contrast to existing risk scoring
systems, CovEWS provides real-time continuous risk assessment that accounts
for a large set of short-term and long-term risk factors associated with COVID-19
related mortality, is automatically derived from readily available EHR data, and
was externally validated using data from multiple hospitals, diverse patient
groups, and across time frames. Accessible risk assessment from readily available
EHRs is especially important in the ongoing COVID-19 pandemic since access
to advanced clinical lab testing and imaging techniques may be limited in
many hospitals. CovEWS allows for critical time in clinical decision making,
even without access to specialised lab tests or advanced diagnostic equipment.
Prospective studies are needed to conclusively establish if the availability of early
warnings for COVID-19 related mortality through CovEWS improves patient
outcomes compared to the standard of care.
5 Data availability
Accredited users may license the TriNetX COVID-19 research and Optum de-
identified COVID-19 electronic health record databases used in this study at
TriNetX and Optum, respectively.
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Figure S4: During training the model is provided with EHR data, including
lab tests, clinical measurements, and information about pre-existing conditions.
Before the data is fed to the model, the preprocessing phase handles missing
values and standardises scaling of each covariate (Section S.5). CovEWS was
trained on the training fold of the Optum cohort, and evaluated on the held-out
Optum test cohort, the Optum Future cohort and the external TriNetX cohort
(Section S.2). The proposed model accommodates the effect of time-varying
and nonlinearly interacting covariates and is trained using partial likelihood as
detailed in Section S.7. Section S.5 presents further details on preprocessing.
S Methods
S.1 Overview
The overall pipeline of the method is shown in Figure S4. We refer to Section S.6.4
for a detailed presentation of the predictive model used by CovEWS and Figure S6
for a detailed diagram of the model architecture.
S.2 Data Collection
We used data collected by two federated networks of healthcare organisations:
Optum. The Optum de-identified COVID-19 electronic health records database
includes de-identified electronic medical records and clinical administrative data
including bedside observations and laboratory data from a geographically diverse
set of healthcare institutions in the United States (US). The EHR data was
sourced from more than 45 provider groups and integrated delivery networks.
We used Optum cohort data collected between 21st March and 5th June 2020,
and another cohort separated in time from 6th June to 13th July 2020 for our
analysis.
TriNetX. TriNetX is a global health research network providing a de-identified
dataset of electronic medical records (diagnoses, procedures, medications, labora-
tory values, genomic information) including patients diagnosed with COVID-19.
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Table S3: Comparison of the percentage of COVID-19 diagnosed patients without
(w/o) a recorded SARS-CoV-2 test result across the analysed datasets (Optum,
Optum Future, TriNetX). The higher fraction of COVID-19 diagnoses without a
recorded SARS-CoV-2 test result in the Optum cohort compared to the Optum
Future cohort is likely a result of the available testing resources having been more
scarce early on in the pandemic. Since the Optum database indicates a generally
high testing ratio substantiating COVID-19 diagnoses, the relatively higher
percentage of COVID-19 diagnoses without corresponding tests in TriNetX is
likely a result of inconsistent coding of SARS-CoV-2 tests early in the pandemic.
Optum Optum Future TriNetX
COVID-19 diagnoses w/o test results [%] 6.31 0.00 37.92
The data is de-identified based on standard defined in Section §164.514(a) of
the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule.
The process by which Data Sets are de-identified is attested to through a formal
determination by a qualified expert as defined in Section §164.514(b)(1) of the
HIPAA Privacy Rule. We used TriNetX cohort data collected between 21st
March and 25th June 2020 from 24 healthcare organisations in the US, Australia,
Malaysia and India for our analysis.
Data Quality. Both Optum and TriNetX as well as the data providing health-
care institutions applied quality control steps to their data, but these procedures
are not standardised neither across the federated networks nor across healthcare
institutions. Varying levels of data quality across EHRs collected at different
healthcare institutions and networks are therefore expected. However, hetero-
geneous data quality standards are characteristic for real-world data collected
at different healthcare institutions. By evaluating CovEWS against an external
test cohort from healthcare institutions with data collection policies different
from our training cohort, we are able to give a fair assessment as to how robust
and transferable CovEWS is in presence of realistic variations in data quality.
Inclusion Criteria. We only included patients that were COVID-19 positive in
our analysis. In both datasets, we considered patients COVID-19 positive if they
either (i) were diagnosed with any of the International Statistical Classification of
Diseases and Related Health Problems 10th revision (ICD-10) codes J12.89, J20.8,
J40, J22, J98.8, and J80 together with B97.295, or (ii) had a positive COVID-19
lab test result (Table S3). For patients identified as COVID-19 positive via ICD
diagnosis codes, we used the date of diagnosis as the reference diagnosis date for
our analyses. For those patients identified as COVID-19 positive via a positive
5The listed criteria correspond to the Centers for Disease Control and Prevention (CDC)
COVID-19 coding guidelines effective February 20, 2020 (see https://www.cdc.gov/nchs/data/
icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.
pdf.
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lab test, we used the date of the test sample collection as the diagnosis date. For
patients with both a positive COVID-19 lab test and diagnosis, the available
diagnosis date took precedence. For the subgroup of patients that were not
hospitalised, we included all patients that were neither admitted to a hospital as
inpatients nor an intensive care unit (ICU) at any point according to their EHRs.
We note that it is possible that hospitals did not in all cases record inpatient
hospital admissions and ICU admissions in their respective EHRs - which may
explain the observed non-zero rate of intubations in the non-hospitalised group.
Membership in the Asian, Caucasian and Black or African American subgroups
was mutually exclusive in the underlying EHR data model, and a patient could
therefore only be assigned to one of the subgroups. In contrast, hispanic ethnicity
was assigned in conjunction with any of the previous race categorisations.
Feature Selection. We selected EHR-derived covariates for inclusion as input
variables for CovEWS based on (i) previously published research on clinical risk
factors for COVID-19 [26, 27, 28], and (ii) expert input from several medical
professionals involved in the treatment of COVID-19 patients. In addition, we
aimed to include both short-term and long-term risk factors for COVID-19
related mortality due to the continuous real-time evaluation of CovEWS. We
present the list of all included model input covariates including their p-values in
Table S4, and their distributions across the datasets in Table 1.
Table S4: Descriptions, Logical Observation Identifiers Names and Codes
(LOINC) codes (if available), and p-values for each input covariate used by
CovEWS. The p-values were calculated using Wald’s χ2 tests for effect (H0 =
no effect) of the coefficients in CovEWS (linear) corresponding to the respective
input covariates on the Optum training cohort.
Covariate Description p-value
Sex - 0.41
Age - < 0.005
Weight - 0.92
Height - 0.80
Body Mass Index (BMI) - 0.85
Intubation Whether or not the patient is in-
tubated
0.04
Temperature Body temperature (LOINC: 8310-
5 on TriNetX)
0.89
SpO2 Oxygen saturation by pulse oxime-
try (LOINC: 59408-5)
< 0.005
Heart rate - 0.75
Respiratory rate - 0.32
Systolic blood pressure - 0.01
Diastolic blood pressure - < 0.005
Kidney disease see Table S5 0.05
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Table S4 cont.
Ischemic heart disease see Table S5 0.04
Other heart disease see Table S5 0.01
Cerebrovascular disease see Table S5 0.20
Hypertension see Table S5 0.03
Diabetes see Table S5 0.15
Hyperlipidemia see Table S5 0.17
Cancer see Table S5 0.65
Dyspnea see Table S5 0.42
COPD see Table S5 0.18
Asthma see Table S5 0.80
Pulmonary embolism see Table S5 0.58
Connective tissue disease see Table S5 0.84
Inflammatory bowel disease see Table S5 0.99
Osteoarthritis see Table S5 0.37
Rheumatoid arthritis see Table S5 0.79
HIV see Table S5 0.97
Smoking (never) - 0.81
Smoking (previous) - 0.61
Smoking (current) - 0.84
Smoking (unknown) - 0.85
White blood cells White blood cell count (LOINC:
26464-8)
< 0.005
Neutrophil Neutrophils per 100 leukocytes in
blood (LOINC: 26511-6)
< 0.005
Lymphocytes Lymphocytes per 100 leukocytes
in blood (LOINC: 26478-8)
< 0.005
Eosinophil Eosinophils per 100 leukocytes in
blood (LOINC: 26450-7)
0.38
Basophil Basophils per 100 leukocytes in
blood (LOINC: 30180-4)
0.33
Platelets Platelets [#/volume] in blood
(LOINC: 26515-7)
0.28
C-reactive protein C-reactive protein [mass/volume]
in serum or plasma (LOINC: 1988-
5)
0.52
hs. C-reactive protein C-reactive protein [mass/volume]
in serum or plasma by high sensi-
tivity method (LOINC: 30522-7)
< 0.005
Procalcitonin Procalcitonin [mass/volume] in
serum or plasma (LOINC: 33959-
8)
0.46
Fibrin D-dimer Fibrin D-dimer Fibrinogen Equiv-
alent Units (FEU) [mass/volume]
in platelet poor plasma
0.13
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Table S4 cont.
Ferritin Ferritin [mass/volume] in serum
or plasma (LOINC: 2276-4)
0.12
Cardiac troponin T Cardiac troponin T
[mass/volume] in serum or
plasma (LOINC: 6598-7)
0.42
Creatinine Creatinine [mass/volume] in
Serum or Plasma (LOINC:
2160-0)
0.03
Lactate dehydrogenase Lactate dehydrogenase [enzy-
matic activity/volume] in serum
or plasma (LOINC: 2532-0,
14804-9)
0.01
Gamma glutamyl transferase Gamma glutamyl transferase
[enzymatic activity/volume]
in serum or plasma (LOINC:
2324-2)
0.69
Aspartate aminotransferase Aspartate aminotransferase [enzy-
matic activity/volume] in serum
or plasma (LOINC: 1920-8)
0.10
Creatine kinase Creatine kinase enzymatic activ-
ity/volume] in serum or plasma
(LOINC: 2157-6)
0.60
Bilirubin Bilirubin [mass/volume] in serum
or plasma (LOINC: 1975-2)
0.28
Albumin Albumin [mass/volume] in serum
or plasma (LOINC: 1751-7)
< 0.005
Interleukin 6 (IL-6) Interleukin 6 [mass/volume] in
serum or plasma (LOINC: 26881-
3)
0.68
pH pH of blood (LOINC: 2744-1,
2746-6)
< 0.005
PCO2 Carbon dioxide [partial pressure]
in arterial blood (LOINC: 2019-8)
0.02
PaO2 Oxygen [partial pressure] in arte-
rial blood (LOINC: 2703-7)
0.63
HCO3 Bicarbonate [moles/volume] in
blood (LOINC: 1959-6, 1960-4)
0.17
CO2 Carbon dioxide, total
[moles/volume] in serum or
plasma (LOINC: 2028-9)
0.21
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Figure S5: Distributions of the number of observations per patient (y-axis, log
scale, violin plots) for time-varying covariates (x-axis) in the Optum and TriNetX
datasets for patients that have at least one observation of a given covariate. The
percentage of patients with no observation for each covariate is shown in Table 1.
Data Characteristics. The cohort statistics of the two datasets are presented
in Table 1, the ICD-9 and ICD-10 codes corresponding to the diagnoses shown
in Table 1 are given in Table S5, and the number of observations per patient
for time-varying covariates for the two datasets is visualised in Figure S5. As is
characteristic for clinical data collected in real-world contexts, missing covariates
are common in both datasets. Missingness in real-world EHR data is caused
primarily by differences in laboratory testing guidelines, data collection practices,
available testing resources and measurement devices between hospitals, and may
in some cases depend on patient status and preferences of clinical staff. For
example, Table S6 compares the missingness between the Optum test set and
the non-hospitalised patient subgroup of the Optum test set. In contrast to
traditional clinical studies, realistic missingness patterns in both the training
and evaluation datasets are a desirable feature in the context of our study as
CovEWS is designed to be deployed in clinical contexts with similar missingness,
and therefore has to be trained and evaluated in the presence of missingness
patterns seen across a representative range of heterogeneous hospitals. Covariates
were mostly balanced across the Optum and TriNetX datasets. The primary
differences were a higher observed mortality rate, and higher ratios of intubations,
connective tissue disease, and rheumatoid arthritis in the TriNetX data compared
to the Optum data. In addition, we note that the majority of admissions were
recorded as being of the ”Unknown” type in the TriNetX database. Since the
large fraction of unknown admission entries limited potential admission outcome
analyses, we reported hospital and ICU admission outcomes as not available
for TriNetX (Table 1). In compliance with the HIIPA Privacy Rule Section
§164.514(a), patients’ exact dates of death were not available to protect patient
privacy. In our analysis, we therefore imputed the last recorded EHR entry
date as the reference date of death for deceased patients. The actual dates of
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Table S5: International Statistical Classification of Diseases and Related Health
Problems (ICD) codes corresponding to the disease classifications and symptoms
used in our analysis. HIV = Human Immunodeficiency Virus, COPD = Chronic
Obstructive Pulmonary Disease.
Disease classification ICD-9 ICD-10
Kidney disease 585 - 586 N18 - N19
Ischemic heart disease 410 - 414 I20 - I25
Other heart disease 390 - 398, 401 - 405, 416 - 417,
420 - 429, 115.03, 115.04, 115.13,
115.14, 115.93, 115.94
I27 - I52
Cerebrovascular disease 430 - 434 I60 - I69
Hypertension 401 - 405 I10 - I15
Diabetes 249 - 250, 357.2, 366.41 E10 - E14
Hyperlipidemia 272 E78
Cancer 140 - 239 C
Dyspnea 786.1, 786.2, 786.8, 786.9 R06
COPD 496, 491.21, 491.22 J44
Asthma 493 J45
Pulmonary embolism 415 I26
Connective tissue disease 446, 710 - 711, 713, 725, 136.1,
279.8, 517.2, 728.5
I30 - I36
Inflammatory bowel disease 555 - 556 K50 - K51
Osteoarthritis 715 M15 - M19
Rheumatoid arthritis 274, 712 - 714, 716, 719 M05 - M14
HIV 42 B20 - B24
death may have happened at a later point, and our performance estimates are
therefore potentially underestimating actual predictive performance, since (i)
correct predictions that happened later would mean CovEWS predicted sooner
than we thought for that patient (which is generally harder, see Figure 2), and
(ii) incorrect predictions of CovEWS may actually have been outside of the
prediction time horizon. We believe this approximation of the exact date of
death is therefore an acceptable trade-off, since underestimation of performance
is not as much a concern as overestimation would be.
S.3 Data Normalisation
The EHR data across both data sources used two different, but compatible,
underlying data models consisting of recorded diagnoses, demographics, lab tests,
procedures, medications and clinical observations. For our risk factors of interest,
we converted records from both datasets into a unified data representation. We
used ICD-9 and ICD-10 to extract diagnoses (Table S5), Logical Observation
Identifiers Names and Codes (LOINC) to extract lab tests, Current Procedural
Terminology (CPT), and ICD-9 Clinical Modification (ICD-9-CM) and ICD-10
Procedural Coding System (ICD-10-PCS) to extract intubation events from the
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Table S6: Comparison of missingness (in %), i.e. the fraction of patients that did
not have any record for a specific covariate in their EHR, in several important
clinical covariates between the Optum test set and the non-hospitalised subgroup
of the Optum test set. SBP = Systolic Blood Pressure, RR = Respiratory rate,
WBC = White blood cells, CRP = C-reactive protein.
Cohort SBP RR WBC CRP Albumin Platelets
Optum Test Set 38.56 42.21 48.40 67.81 53.48 48.45
Non-hospitalised 54.00 59.57 64.67 81.10 69.02 64.72
EHR records. For lab tests, we additionally normalised the unit of each category
of lab tests to be the same for each measured record of that category.
S.4 Stratification
We split the Optum cohort used for model development into training (50%),
validation (20%) and held-out test folds (30% of all patients) at random stratified
by patient age, gender, presence of mortality events, presence of intubation events,
presence of ICU admission and presence of a human immunodeficiency virus
(HIV) diagnosis. We added HIV to the set of stratification covariates since its low
prevalence could otherwise have led to imbalances in this risk factor across the
folds. Stratification produced balanced cohorts across the three folds (Table 1).
The Optum training fold was used to train CovEWS, the validation fold was
used to select the optimal hyperparameter configuration for CovEWS, and the
held-out test fold was used in addition to the external TriNetX test cohort to
evaluate the out-of-sample generalisation performance of CovEWS.
S.5 Preprocessing
Discrete covariates with p different values were transformed into their one-hot
encoded representation with one out of p indicator variables set to 1 to indicate the
discrete value for this patient. All continuous features were standardised to have
zero mean and unit standard deviation using observed covariate distribution
on the Optum training fold. Missing values of continuous covariates were
imputed in an iterative fashion using multiple imputation by chained equations
(MICE) [29]. After the preprocessing stage, continuous input features were
standardised and fully imputed, and discrete input covariates were one-hot
encoded. All preprocessing operations were derived only from the training fold,
and na¨ıvely applied without adjustment to other folds and datasets in order to
avoid information leakage.
S.6 Method
We adopt a variation of the widely used Cox proportional hazard model that is
adapted to accommodate nonlinear and time-varying effects of covariates on the
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log-hazard function. In the following, the basics of time-to-event analysis that
is the main subject of this paper is briefly presented. Then we touch upon the
Cox proportional model for continuous-time covariates that is followed by the
modifications we applied to this model to prepare it for the current work.
S.6.1 Survival Analysis
Survival analysis which is also known as Time-To-Event (TTE) analysis included
a large body of work consisting of mathematical tools to give a statistical analysis
of the time duration until a specified event occurs. In the current work, the
event is defined to be the time when a patient dies.
An important tool in time-to-event analysis is hazard function. In discrete-
time setting, (e.g. if times are given in specified periods) the hazard function is
a conditional probability defined in discrete-time as
h(t|x) = P (T = t|T ≥ t; x), t = 1, 2, . . . (1)
that represents the risk of dying at time t if the patient has survived until that
time. The relevant covariates of the patients up to time t are encapsulated in the
vector x ∈ Rd. Age, sex, and lab tests are examples of such covariates that can
take either binary or standardised real values after preprocessing. Intuitively,
the hazard function captures the underlying dynamics of the transition of the
condition of the patient from alive to dead. The larger h is at time t, the more
likely it is for the patient to die at time t.
Another useful function is called survival function that is denoted by S(t)
and in discrete-time defined as
S(t) = P (T > t) =
t∏
s=1
(1− hs). (2)
Similar functions can be defined in the continuous-time regime. Let Tc be the
continuous survival time with the probability density function fc and cumulative
distribution function Fc. Similar to Equation (2), the continuous survival function
represents the probability of surviving until time t that is defined as
Sc(t|x) = P (Tc > t|x) = 1− Fc(t|x). (3)
Likewise, the continuous hazard function is defined as
hc(t|x) = lim
∆t→0
P (t ≤ Tc ≤ t+ ∆t|Tc ≥ t; x)
∆t
. (4)
Notice that unlike discrete hazard function (1), the continuous hazard function (4)
is not a probability distribution and can take values larger than one.
The last useful function in continuous survival analysis is the cumulative
hazard function
Hc(t) =
∫ t
0
hc(u)du. (5)
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The connection between these quantities can be simply derived:
hc(t) =
fc(t)
Sc(t)
, (6)
Sc(t) = exp(−
∫ t
0
hc(u)du) = exp(−Hc(t)), (7)
fc(t) = hc(t) exp(−
∫ t
0
hc(u)du) = hc(t) exp(−Hc(t)). (8)
Before introducing the simple yet flexible Cox model, we discuss a few
important issues that must be taken into account in survival analysis.
Censoring. What makes the survival analysis different from a simple regression
from the covariates x to T – observed duration up to the occurrence of the
event – is the concept of censoring. An observation is called censored – or more
precisely right-censored – if its survival time has not been fully observed. There
are several causes for a censored observation. For example, if a patient is not
under observation when the event occurs or if the information of the patient is
lost for some reason, only a lower bound to the time-to-event T is observed that
is the last time the condition of the patient is recorded.
Discrete vs. Continuous. Although time is a continuous physical quantity,
in practice, it is measured at discrete points. Especially, in medical sciences,
the condition of the patient is measured on a regular daily or bi-daily basis.
This implies that even though the change of the covariates of a patient occurs
at certain points of time, the exact time is not known. The transition point
is only known up to the resolution of the measurement. We assume the time
at which an event of interest occurs is denoted by T . As the resolution of the
measurement is hours in the datasets used in the current work, T = t refers to
an event that occurs within the tth hour after the patient is admitted to the
hospital and its health condition is recorded.
Ties. In the limited resolution measurement of time, some observations may
have the same survival times, e.g., two patients die on the same day even though
it is extremely unlikely that both die at the same moment. However, even in
continuous time data, ties may occur which is a hint of underlying discrete
sampling in time.
A major difference between continuous and discrete-time survival analysis is
that the hazard function is a probability distribution in discrete settings while
it can take any positive value in continuous settings. However, the traditional
continuous-time approach can still be used for discrete event times especially
when the measurements are equally spaced.
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S.6.2 Cox Hazards Model
The most widely known model in the analysis of continuous survival time is
Cox’s proportional hazard model [30] that parameterizes the hazard function as
hc(t|x) = h0(t) exp(βTx), (9)
where h0 is called the baseline hazard that is modulated by the effect of covariates
via exp(βTx). Notice that in the traditional Cox model (9) the covariates x are
assumed constant over time. Consequently, the temporal variation of the hazard
function is separated from the influence of the covariates.
S.6.3 Time-varying Covariates
In many experimental settings, the assumption of time-invariant covariates in (9)
does not hold. For example, many entries in the electronic health records such
as heart rate, temperature, and blood measurements do not remain constant
over the course of the hospitalisation of a patient. Therefore, the traditional
Cox model (9) is extended to a time-varying setting by replacing x in (9) with
xt that is the measured covariates at time t. Assume a dataset consists of N
patients indexed by n = 1, 2, . . . , N . As a notational convention, x
(n)
t denotes
the vector of the corresponding covariates to the patient n at time t.
If the Cox model holds and continuous events are observed, the following
function called partial likelihood is maximized to estimate β:
L(β) :=
k∏
i=1
exp(βTx
(i)
ti )∑
j∈R(ti) exp(β
Tx
(j)
t=ti)
, (10)
where t1 < t2 < . . . < tk are the ordered times at which the events occur and
x
(1)
t1 ,x
(2)
t2 , . . . ,x
(k)
tk
are the corresponding set of covariates at those times. Notice
that the equality of the superscript of the covariate vector x
(i)
ti (patient’s index)
and the subscript of time ti emphasizes the continuous event times and the fact
that at most one patient experiences the event at each time. For the moment,
we assume time is continuous that results in distinct event times. The set R(ti)
is the set of the patient’s indices that are at risk at time ti. Being at risk means
they are alive and can potentially experience the event.
S.6.4 Nonlinear Time-varying Covariates
One clear limitation of (10) that is caused by the definition of the hazard
function (9), is the fact that the exponent of the modulating function exp(βTx)
is a linear function of x. Hence higher order interactions among different
dimensions of the covariate vector cannot be captured by this method. To
improve the expressiveness of the model, we replace the linear function βTx with
a nonlinear function realised by a neural network. Let φ(·;θ) : Rd → R be the
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function implemented by the neural network and parameterised by θ. Therefore,
the hazard model is represented as
h(t|x) = h0(t) exp(φ(xt;θ)), (11)
where h0(t) is the baseline population-level hazard that is independent of the
associated covariates to each patient. Time-varying covariates are transformed by
the function φ(·;θ) to log-hazard. The parameters θ are learned via maximising
the partial log-likelihood [30]. Despite traditional Cox proportional hazard
model where the gradient and Hessian can be computed analytically, here, we
use automatic differentiation to compute gradients with respect to θ. The
nonlinear function φ(·;θ) is implemented as a 2−layer multilayer perceptron –
see Section S.6 for a detailed description. The hazard function (11) estimates
the instantaneous risk of death at each time for each patient. Integrating with
respect to time and exponentiating the result gives the survival function defined
as
S(t|x0:t) = P (T > t|x0:t) = exp
(
−
∫ t
0
h(u|xu)du
)
. (12)
Notice that x0:t denotes the set of covariates until time t, meaning that, the
probability of survival up to time t depends on the history of the covariates.
The partial likelihood (10) is re-written as
L(θ) :=
k∏
i=1
exp(φ(x
(i)
ti ;θ))∑
j∈R(ti) exp(φ(x
(j)
t=ti ;θ))
. (13)
To give an intuition of (13), observe that the partial log-likelihood that is
computed by taking logarithm of the right-hand side of (13) will consist of k
terms corresponding to k observed events. The parameter vector θ is perturbed
such that the hazard increases for the covariates of a patient who dies at time ti
while it decreases for the covariates of the patients who remain alive at ti.
S.6.5 Resolving Ties
Even though we adopt a continuous-time approach due to the non-normalised
parametric form of the hazard function (9) and the resultant partial likeli-
hood (13), the ties can still occur as we work in hourly resolution. Hence, it
is possible that two patients die at the same time. When an event occurs for
two patients at the same time, the partial likelihood (13) is not valid anymore.
Several methods exist in the literature to break the ties and remove the ambiguity
such as average partial likelihood [30] and Berslow’s method [31] that lives on
two ends of a spectrum. The former takes average among all possible orders of
the events that can break the tie. Hence, it is the most accurate method but
computationally prohibitive. The latter gives a partial likelihood almost exactly
like the original Cox likelihood by assuming that every ordering of tied events
results in the same partial likelihood. This method gives a crude estimate but is
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Figure S6: Schematic illustration of a neural network realisation of the nonlinear
exponent of the time-varying Cox hazard function with L = 1 hidden layers with
Ndim hidden units and one output layer.
easy to implement. A midway approach that we adopted in this work is called
Efron’s tie-breaker [32]. In this method, a weighted average likelihood of tied
cases is subtracted from the denominator of Equation (13). Efron’s method gives
good accuracy and is moderately easy to work with – see [32] for details.
S.7 Algorithm Details
Survival analysis by the Cox model is done via maximum likelihood estimation,
where the aim is to maximise the logarithm of (10) in the original Cox’s propor-
tional hazard model and (13) in the nonlinear extension. In the original method
with linear exponent both gradient ∂ logL/∂β and Hessian ∂2 logL/∂2β can
be computed analytically. This is not the case for our proposed extension (13)
with nonlinear exponent. Instead of an analytical gradient, we use automatic
differentiation to compute the gradient ∂ logL/∂θ. Once the gradient is derived,
an appropriate gradient-based method is used to perturb θ in the direction that
increases the partial likelihood.
As mentioned in section S.6.4, the linear exponent βTx in (10) is replaced
with a nonlinear function φ(·;θ). We use a neural network with L hidden
layers to realise this function. The employed network linearly transforms the
input features to a Ndim-dimensional hidden layer. The transformed features
are passed through a leaky rectified linear unit (LeakyReLU) [33] nonlinear
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Table S7: Hyperparameter ranges used for hyperparameter optimisation of
CovEWS and CovEWS (linear). Comma-delimited lists indicate discrete choices
with equal selection probability. Hyperparameters selected after hyperparameter
optimisation (Section S.8) are highlighted in bold.
Hyperparameter Range / Choices
L
in
ea
r
Regularisation strength λ 0.01, 0.1, 1.0
C
ov
E
W
S Number of layers L 1, 2
Number of hidden units Ndim 64, 128, 256
Dropout percentage pdropout 10%, 20%
activation function. The hidden activations are then transformed by a linear
transformation to a single node and finally passes through a tangent hyperbolic
(tanh) activation function. In summary the network function can be represented
as
φ(x;θ) = tanh(W2(LeakyReLU(W1x))), (14)
where θ = {W1,W2} and Wi, i = 1, 2 are the trainable weight matrices of the
network (Figure S6). We used Xavier’s method [34] to initialise the weights θ
of the model. To prevent overfitting, we additionally applied dropout with a
dropout probability of pdropout. In our PyTorch [35] implementation of CovEWS,
we observed stable convergence of our model using the Adam [36] optimiser with
a learning rate of 0.001 for up to 100 epochs.
S.8 Hyperparameter Optimisation
For the methods trained on the Optum training fold (CovEWS and CovEWS
[linear]), we used a systematic approach to hyperparameter optimisation where
each prediction algorithm was given a maximum of 15 hyperparameter optimisa-
tion runs with different hyperparameter configurations chosen at random without
duplicates from predefined ranges (see Table S7). Out of the models generated in
the hyperparameter optimisation runs, we then selected the model that achieved
the highest specificity at greater than 95% sensitivity on the validation set of
the Optum cohort.
S.9 Postprocessing and Calibration
After training CovEWS using the Optum training cohort, the predicted hazard
for a patient with state x is the hazard function h(t|x) eq. (9) evaluated at
t = 128 hours (≈ 5.33 days) given the current patient covariates x and under the
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Table S8: Optimal thresholds of CovEWS scores to maximise specificity at
greater than 85%, 90% and 95% sensitivity (Sens.) for each prediction horizon
as selected on their respective receiver operator characteristic (ROC) curves on
the held-out Optum test set.
Sens. 1 hour 2 hours 4 hours 8 hours 16 hours 24 hours 48 hours 96 hours 192 hours
85% 61 62 56 54 51 48 45 39 36
90% 44 44 42 41 39 38 38 32 27
95% 34 34 33 31 28 27 27 22 19
assumption that patient covariates stay constant. To produce CovEWS scores,
we additionally apply post-processing using a percentile transformation that
converts h(t|x) into the percentile of patient states in the Optum validation set
that are assigned a lower h(t|x) than the evaluated patient state x. We chose to
output CovEWS scores in form of percentiles to aid in the clinical interpretation
of CovEWS as a risk score relative to a representative set of reference states,
and to discourage interpretation as a mortality probability. Interpretation of
CovEWS scores as a mortality probability is difficult since the mortality risk
of a patient depends on their uncertain future trajectory and the prediction
horizon, and is influenced by clinical interventions that may be initiated in
the future. As shown in Figure 1, patients’ states may change rapidly and
frequently, and clinical interventions can significantly and positively alter the
trajectory of patients. We also verified experimentally that, when interpreted as
a probability of mortality, CovEWS scores overestimate the actually observed
probability of death on the Optum and TriNetX test sets since patients’ states
may improve, due to intervention or otherwise, between the prediction time
and the end of the prediction horizon (Figure S7; similar results with CovEWS
[linear] Figure S8). We, therefore, decided to instead output CovEWS scores as
relative risk percentiles between 0 and 100 that discourages interpretation as a
probability of mortality. To aid in the use of CovEWS, the following Section S.10
outlines calibrated thresholds that can be used to maximise specificity at the
desired target level of sensitivity for different prediction horizons.
S.10 Thresholds
A key question for clinical decision making is which threshold should be used for
CovEWS scores to indicate severe risk, and potentially trigger an automated
warning. To provide guidance in choosing the appropriate CovEWS score de-
pending on the desired trade-off between sensitivity and specificity, we evaluated
the optimal observed thresholds of CovEWS scores for various target sensitivity
levels using their respective receiver operator characteristic (ROC) curves for
each prediction horizon (Table S8). Optimal score thresholds to maximise speci-
ficity at high levels of sensitivity were between 61 and 36, 44 and 27, and 34 and
19 depending on the prediction horizon for target sensitivity levels greater than
85%, 90% and 95%, respectively. We note that lower thresholds are necessary to
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achieve high sensitivity for prediction horizons farther in the future as patients’
deterioration has to be identified earlier in its progression.
S.11 Feature Importance
Highlighting the clinical risk factors that positively or negatively influenced
CovEWS to output a certain score is of high utility as it enables clinical users
to contextualise CovEWS scores, and, in some cases, these highlights could
potentially even point towards opportunities for timely intervention. We utilised
the differentiability of our prediction model as outlined in Section S.7 to provide
a real-time visualisation of the clinical covariates that are most important for
CovEWS at any given time point (see Figure 1 for an example). To compute
the importance scores at each time point, we used the Integrated Gradients (IG)
[37] method that calculates relative importance scores ai ∈ (−100%, 100%) for
each input feature xt,i in the feature vector xt with i ∈ [0 . . d− 1] where d is the
number of input features. We used IG with the mean feature vector x¯t across
the Optum training set as a reference, calculated 50 intermediate steps for each
explained xt, and normalised ai to the range of (−100%, 100%) by dividing each
ai by the sum Σ
d−1
i=0 |ai| of all feature attributions for xt. To obtain a timeline
of attributions as shown in Figure 1, we calculate attributions ai whenever a
change in patient status was recorded in the patient’s EHR.
S.12 Baselines
In our analysis, we compared the performance of CovEWS to the following
existing generic and COVID-19 specific clinical risk scores, and baselines:
CovEWS (linear). A linear time-varying survival Cox model as described in
Section S.6.3 trained using the same Optum training set and using the same
pipeline as the non-linear CovEWS. We used the implementation provided in
version 0.24.8 of the lifelines [20] Python package.
COVID-19 Estimated Risk for Fatality (COVER F). The COVER F
scoring system for COVID-19 as described in [19]. Since COVER F uses a single
flag for any heart disease diagnosis, we aggregated all diagnoses in the diagnosis
categories ischemic heart disease, pulmonary embolism, other heart diseases in
our dataset into one single joint diagnosis code if any diagnosis in those three
categories was present. All other input features used by COVER F were direct
matches with the input covariates of the same name also used by CovEWS
(Table 1).
Sequential Organ Failure Assessment (SOFA). SOFA scoring is com-
monly used in clinical contexts to indicate the risk of organ failure in critical
patients. We, therefore, used SOFA as a generic risk scoring baseline that was
not specifically designed for COVID-19 to demonstrate the comparative benefits
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(b) External TriNetX Test Set
Figure S7: Calibration plots [38] and counts of observed predictions of CovEWS
on the held-out Optum test set (left) and the external TriNetX test set (right)
when interpreting the predicted risk percentile of CovEWS as the probability of
a mortality event being observed within the next 24 hours. The reference time
point for those patients that did not have an observed mortality event is the date
of their respective last observed EHR entry. When interpreted as a patient’s
mortality probability, CovEWS overestimates the risk since it can not account a
priori for clinical interventions and potential future patient trajectory changes
that may occur rapidly and frequently. Direct interpretation of CovEWS scores
as a mortality probability is discouraged, and CovEWS scores should instead be
seen as a relative risk score to stratify patients into risk groups (Section 3).
in the predictive performance of a COVID-19 specific risk scoring system. Since
we did not have FiO2 values available in our EHR datasets, we assumed a default
FiO2 value of 21% (equal to the fraction of oxygen in inhaled air) for patients
that were not intubated, and an average of 71% for patients that are intubated
(FiO2 is often set to 100% initially and then progressively lowered as the patient
stabilises, see e.g. [39] for an example). In addition, we did not have access to
Glasgow coma scale (GCS) scores in the EHRs, and potential additional points
from a high GCS score (a maximum of +4) were therefore not reflected in our
calculated SOFA scores.
Yan et al. 2020. Yan et al. [17] derived a simple and interpretable decision
rule using three features (Figure 2 in [17]) for mortality prediction in COVID-19
patients from data collected from 485 COVID-19 positive patients seen in Wuhan,
China. In their validation cohort, the decision rule showed a respectable cross-
validated prediction performance of 96.1 ± 0.03 (mean ± standard deviation,
35 September 1, 2020
CovEWS (linear) Calibration
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Fr
ac
tio
n 
of
 P
o
si
tiv
es
0
500
1000
1500
2000
0.00 0.25 0.50 0.75 1.00
Predicted
co
u
n
t
(a) Held-out Optum Test Set
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
Fr
ac
tio
n 
of
 P
o
si
tiv
es
0
100
200
300
400
500
0.00 0.25 0.50 0.75 1.00
Predicted
co
u
n
t
(b) External TriNetX Test Set
Figure S8: Calibration plots [38] and counts of observed predictions of CovEWS
(linear) on the held-out Optum test set (left) and the external TriNetX test set
(right) when interpreting the predicted risk percentile of CovEWS (linear) as the
probability of a mortality event being observed within the next 24 hours. The
reference time point for those patients that did not have an observed mortality
event is the date of their respective last observed EHR entry. Like the version of
CovEWS that models non-linear interactions, CovEWS (linear) overestimates
mortality risk when interpreted as a patient’s mortality probability.
5-fold cross validation) [17]. All input features used by Yan et al. [17] were
direct matches with the input covariates of the same name also used by CovEWS
(Table 1).
Liang et al. 2020. Liang et al. [18] developed a prediction model for critical
COVID-19 related illness using data from 1 590 patients seen at 575 medical
centers in China using deep learning and 10 input covariates, including observed
X-ray abnormalities. On three external cohorts from different Chinese provinces,
they reported a predictive performance in terms of concordance index (c-index) of
0.890, 0.852 and 0.967 for predicting critical illness under the missingness of input
covariates, respectively. Since we did not have access to radiologic assessments in
our EHR datasets, we evaluated their model with the X-ray abnormality covariate
missing for all evaluated patients (i.e. set to zero). To the best of our knowledge,
Liang et al. [18] did not specify which co-morbidities were included in their
collected dataset. However, their study reports a maximum of 6 co-morbidities
diagnosed in one patient. In our evaluation, we counted existing patient diagnoses
of pulmonary embolism, kidney disease, inflammatory bowel disease, asthma,
rheumatoid arthritis, and diabetes towards these 6 co-morbidities.
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S.13 Software
The source code used for developing CovEWS and for conducting the pre-
sented experiments and analyses was implemented using Python (version 3.7),
scikit-learn (version 0.22.2), numpy (version 1.19.1), scipy (version 1.4.1),
pandas (version 1.5.0), PyTorch (version 1.5.1), and lifelines (version 0.24.8).
All plots shown were generated using the ggpot2 R package [40].
S.14 Hardware
We used the high-performance computing (HPC) infrastructure provided by the
Personalised Healthcare Informatics group at F. Hoffmann-La Roche Ltd to run
the presented experiments. The compute nodes used 1st and 2nd generation
Intel Xeon Platinum 8000 series processors and had access to 72 GB random
access memory (RAM) each.
S.15 Performance Evaluation
In addition to the results presented in the main body of this work, we also present
Receiver operator characteristic (ROC) curves for CovEWS for various prediction
horizons between 1 and 192 hours evaluated on the held-out Optum test set
(Figure S9) and the external TriNetX test set (Figure S10), the same ROC curves
for CovEWS (linear) (Figure S11 an Figure S12) a comparison of CovEWS, Time
Varying Cox [20], COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18]
at various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity
and specificity at greater than 95% sensitivity (Spec.@95%Sens.) for predicting
COVID-19 related mortality on the held-out Optum test set (Table S9), on the
external TriNetX test set (Table S10), on the Optum Future cohort (Table S15),
and on the Black or African American (Table S11), Hispanic (Table S12), Asian
(Table S13), Caucasian (Table S14) and non-hospitalised (Table S16) subgroups
of the Optum test set.
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Figure S9: Receiver operating characteristic (ROC) curves for CovEWS for
various prediction horizons between 1 and 192 hours evaluated on the held-out
Optum test set. The black dot indicates the optimal decision threshold for each
prediction horizon selected on the Optum validation set as the closest point on
the ROC curve to the top left coordinate (closest-to-top-left heuristic).
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CovEWS Receiver Operating Characteristic (TriNetX)
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Figure S10: Receiver operating characteristic (ROC) curves for CovEWS for
various prediction horizons between 1 and 192 hours evaluated on the external
TriNetX test set. The black dot indicates the optimal decision threshold for each
prediction horizon selected on the Optum validation set as the closest point on
the ROC curve to the top left coordinate (closest-to-top-left heuristic).
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CovEWS (linear) Receiver Operating Characteristic (Optum Test Set)
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Figure S11: Receiver operating characteristic (ROC) curves for CovEWS (linear)
for various prediction horizons between 1 and 192 hours evaluated on the held-out
Optum test set. The black dot indicates the optimal decision threshold for each
prediction horizon selected on the Optum validation set as the closest point on
the ROC curve to the top left coordinate (closest-to-top-left heuristic).
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Figure S12: Receiver operating characteristic (ROC) curves for CovEWS (linear)
for various prediction horizons between 1 and 192 hours evaluated on the external
TriNetX test set. The black dot indicates the optimal decision threshold for each
prediction horizon selected on the Optum validation set as the closest point on
the ROC curve to the top left coordinate (closest-to-top-left heuristic).
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Table S9: Comparison of CovEWS, CovEWS (linear), COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18] at
various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity and specificity at greater than 95% sensitivity
(Spec.@95%Sens.) for predicting COVID-19 related mortality on the held-out Optum test set. Values are the median and the
95% confidence intervals (CIs, in parentheses) obtained via bootstrap resampling with 200 samples. †= significant at p < 0.05
to CovEWS (one-sided Mann-Whitney-Wilcoxon, Bonferroni corrected). Best results for each metric are highlighted in bold.
Held-out Optum Test Set
Model AUC AUPR F1 Sensitivity Specificity Spec.@95%Sens.
1
h
o
u
r
CovEWS 97.2 (96.7, 97.7) 69.2 (66.1, 72.3) 56.1 (54.2, 58.3) 92.8 (90.9, 94.7) 92.4 (91.9, 92.8) 89.3 (83.0, 91.6)
CovEWS (linear) †97.0 (96.5, 97.4) 69.9 (66.9, 72.8) †53.3 (51.4, 55.5) †90.1 (88.2, 92.2) †91.8 (91.4, 92.3) †85.8 (83.1, 87.9)
Liang et al. 2020 †86.7 (85.4, 88.2) †32.4 (29.5, 36.1) †30.2 (28.6, 32.3) †82.0 (79.2, 85.6) †80.1 (79.3, 80.7) †40.0 (32.8, 60.4)
COVER F †65.6 (63.8, 67.8) †07.9 (07.1, 08.6) †14.7 (13.4, 15.9) †67.5 (63.9, 71.0) †58.1 (57.4, 58.9) †09.4 (04.7, 16.2)
SOFA †90.7 (89.5, 91.8) †46.4 (42.5, 50.1) †38.8 (36.6, 41.0) †83.8 (81.2, 86.0) †86.2 (85.6, 86.8) †00.0 (00.0, 65.3)
Yan et al. 2020 †82.8 (81.6, 84.0) †53.5 (52.2, 54.9) †29.0 (27.4, 30.6) †89.3 (87.2, 91.5) †76.3 (75.6, 77.0) †00.0 (00.0, 00.0)
2
h
o
u
r
s
CovEWS 97.2 (96.6, 97.6) 68.1 (65.1, 71.4) 56.1 (53.9, 58.3) 93.0 (91.3, 95.0) 92.4 (91.9, 92.8) 89.6 (82.6, 91.8)
CovEWS (linear) †97.0 (96.4, 97.4) 68.7 (65.7, 71.9) †49.7 (47.5, 51.9) †92.2 (90.2, 93.9) †90.1 (89.6, 90.7) †85.6 (82.6, 88.5)
Liang et al. 2020 †87.0 (85.6, 88.5) †32.5 (29.5, 36.3) †30.5 (28.9, 32.5) †82.8 (80.3, 86.4) †80.1 (79.3, 80.7) †41.3 (32.9, 60.4)
COVER F †65.6 (63.6, 67.8) †07.9 (07.0, 08.6) †14.6 (13.4, 15.8) †67.4 (63.8, 70.9) †58.1 (57.4, 58.9) †09.4 (04.7, 16.2)
SOFA †90.6 (89.3, 91.7) †45.7 (41.8, 49.6) †38.5 (36.5, 40.6) †83.2 (80.7, 85.4) †86.2 (85.6, 86.7) †00.0 (00.0, 65.4)
Yan et al. 2020 †82.7 (81.4, 83.9) †53.4 (52.0, 54.8) †28.9 (27.3, 30.5) †89.0 (86.8, 91.4) †76.3 (75.6, 77.0) †00.0 (00.0, 00.0)
4
h
o
u
r
s
CovEWS 97.1 (96.6, 97.5) 66.4 (63.7, 70.0) 54.1 (51.8, 56.2) 93.2 (91.4, 95.1) 91.7 (91.2, 92.2) 89.5 (83.6, 91.8)
CovEWS (linear) †96.9 (96.3, 97.3) 67.3 (64.4, 70.6) †49.5 (47.3, 51.5) †91.8 (89.7, 93.5) †90.1 (89.6, 90.7) †85.2 (83.1, 87.5)
Liang et al. 2020 †87.1 (85.7, 88.6) †32.2 (29.0, 36.1) †30.3 (28.6, 32.3) †83.0 (80.5, 86.2) †80.0 (79.2, 80.5) †45.5 (33.7, 61.9)
COVER F †65.6 (63.7, 67.7) †07.8 (07.0, 08.5) †14.5 (13.3, 15.7) †67.3 (63.9, 71.1) †58.1 (57.4, 58.9) †09.4 (04.7, 16.2)
SOFA †90.3 (89.0, 91.3) †45.0 (41.1, 48.8) †38.1 (36.1, 40.4) †82.6 (79.8, 84.7) †86.2 (85.6, 86.7) †00.0 (00.0, 65.3)
Yan et al. 2020 †82.6 (81.3, 83.9) †53.3 (51.9, 54.7) †28.7 (27.1, 30.3) †89.0 (86.7, 91.4) †76.3 (75.6, 77.0) †00.0 (00.0, 00.0)
8
h
o
u
r
s
CovEWS 97.0 (96.5, 97.5) 63.4 (60.5, 66.9) 51.8 (49.4, 53.8) 93.3 (91.5, 95.1) 90.9 (90.4, 91.4) 89.3 (84.1, 91.0)
CovEWS (linear) †96.7 (96.2, 97.1) 63.4 (60.5, 66.4) †49.2 (47.0, 51.3) †91.9 (89.8, 93.6) †90.1 (89.6, 90.7) †84.7 (82.5, 87.4)
Liang et al. 2020 †86.9 (85.7, 88.4) †32.0 (28.7, 35.9) †30.1 (28.5, 32.2) †83.1 (80.3, 86.3) †80.0 (79.1, 80.5) †39.2 (32.8, 60.2)
COVER F †65.4 (63.4, 67.6) †07.6 (06.9, 08.4) †14.3 (13.1, 15.6) †67.0 (63.4, 70.8) †58.1 (57.4, 58.9) †09.3 (04.7, 16.1)
SOFA †89.7 (88.5, 90.8) †43.5 (40.0, 47.3) †37.5 (35.4, 39.7) †81.4 (78.6, 83.9) †86.2 (85.6, 86.7) †00.0 (00.0, 64.2)
Yan et al. 2020 †82.4 (81.1, 83.6) †52.9 (51.6, 54.2) †28.3 (26.8, 30.1) †88.5 (86.2, 90.8) †76.3 (75.6, 77.0) †00.0 (00.0, 00.0)
1
6
h
o
u
r
s
CovEWS 96.1 (95.6, 96.7) 63.6 (60.2, 67.2) 52.5 (50.1, 54.6) 92.9 (90.9, 94.6) 89.0 (88.4, 89.6) 84.6 (79.3, 88.3)
CovEWS (linear) †95.7 (95.2, 96.2) 63.1 (59.8, 66.7) †52.1 (49.8, 54.3) †88.2 (86.0, 90.2) 89.7 (89.1, 90.3) †79.8 (77.1, 83.5)
Liang et al. 2020 †85.5 (84.2, 87.3) †32.3 (28.8, 36.6) †32.1 (30.5, 34.4) †82.3 (79.6, 85.8) †77.5 (76.6, 78.3) †39.0 (33.1, 57.7)
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COVER F †64.0 (61.9, 66.2) †09.0 (08.1, 09.9) †16.5 (15.1, 17.9) †67.4 (63.8, 71.5) †55.8 (54.8, 56.6) †09.0 (04.7, 15.0)
SOFA †88.2 (87.0, 89.4) †41.5 (38.0, 45.2) †38.1 (35.8, 40.3) †80.3 (77.2, 83.3) †83.5 (82.8, 84.2) †00.0 (00.0, 60.9)
Yan et al. 2020 †80.3 (78.9, 81.6) †53.3 (51.8, 54.9) †29.9 (28.3, 31.6) †87.9 (85.6, 90.3) †72.6 (71.7, 73.7) †00.0 (00.0, 00.0)
2
4
h
o
u
r
s
CovEWS 95.4 (94.7, 96.1) 61.3 (58.1, 65.1) 49.4 (47.2, 51.6) 91.1 (88.7, 93.2) 87.6 (87.0, 88.3) 79.7 (75.1, 84.7)
CovEWS (linear) †95.0 (94.4, 95.6) 61.0 (57.9, 64.4) 50.8 (48.4, 53.0) †87.5 (84.6, 89.7) 89.1 (88.5, 89.8) †77.5 (72.4, 81.3)
Liang et al. 2020 †84.7 (83.2, 86.3) †30.9 (27.6, 34.6) †31.3 (29.7, 33.6) †81.1 (78.3, 84.4) †76.8 (76.0, 77.6) †37.1 (30.8, 52.0)
COVER F †63.7 (61.6, 65.9) †09.0 (08.1, 09.9) †16.5 (15.1, 17.9) †67.0 (63.4, 71.1) †55.2 (54.3, 56.2) †08.8 (04.8, 14.9)
SOFA †87.3 (85.9, 88.6) †39.8 (36.1, 43.4) †37.2 (34.9, 39.4) †78.9 (75.7, 81.9) †83.0 (82.3, 83.8) †00.0 (00.0, 00.0)
Yan et al. 2020 †79.8 (78.7, 81.1) †53.1 (51.7, 54.7) †29.5 (28.0, 31.2) †87.7 (85.3, 90.4) †71.9 (71.1, 72.9) †00.0 (00.0, 00.0)
4
8
h
o
u
r
s
CovEWS 94.7 (93.9, 95.5) 58.2 (54.8, 62.0) 47.4 (45.1, 49.6) 91.2 (88.7, 93.6) 86.4 (85.7, 87.2) 77.5 (71.8, 82.5)
CovEWS (linear) †94.2 (93.4, 94.8) 58.5 (54.7, 62.1) †44.7 (42.4, 46.8) †87.5 (84.9, 90.3) †85.6 (84.9, 86.3) †75.6 (69.7, 79.7)
Liang et al. 2020 †83.0 (81.6, 84.9) †28.2 (24.7, 31.8) †30.1 (28.2, 32.3) †78.3 (75.3, 82.1) †75.9 (75.0, 76.8) †32.7 (25.6, 44.8)
COVER F †63.7 (61.4, 65.9) †09.1 (08.2, 10.1) †16.7 (15.2, 18.1) †67.9 (64.1, 71.9) †54.5 (53.4, 55.6) †08.5 (04.4, 14.3)
SOFA †86.2 (84.7, 87.7) †37.3 (33.9, 40.7) †35.8 (33.3, 38.0) †76.8 (73.1, 80.2) †82.2 (81.5, 83.1) †00.0 (00.0, 00.0)
Yan et al. 2020 †78.5 (77.1, 79.9) †52.2 (50.7, 53.6) †28.7 (27.0, 30.4) †86.3 (83.6, 89.0) †70.8 (69.7, 71.7) †00.0 (00.0, 00.0)
9
6
h
o
u
r
s
CovEWS 93.5 (92.5, 94.4) 54.1 (49.8, 57.7) 43.7 (41.2, 46.1) 85.4 (82.9, 88.1) 86.3 (85.4, 86.9) 72.5 (65.7, 78.2)
CovEWS (linear) †92.7 (91.6, 93.6) 54.8 (50.7, 58.3) †40.1 (37.5, 42.2) †84.0 (80.5, 87.3) †84.4 (83.5, 85.0) †68.7 (64.1, 75.7)
Liang et al. 2020 †81.5 (79.8, 83.3) †24.9 (21.8, 28.3) †27.1 (25.2, 28.9) †76.3 (73.1, 80.6) †74.1 (73.3, 75.1) †32.9 (24.4, 40.1)
COVER F †63.4 (61.0, 65.7) †08.7 (07.7, 09.6) †15.8 (14.2, 17.3) †68.3 (64.6, 72.8) †53.7 (52.5, 54.8) †05.5 (04.1, 13.8)
SOFA †83.9 (82.1, 85.8) †32.9 (29.6, 37.0) †32.2 (29.9, 34.3) †73.1 (69.3, 76.9) †81.4 (80.5, 82.2) †00.0 (00.0, 00.0)
Yan et al. 2020 †77.4 (75.9, 78.9) †50.7 (49.0, 52.2) †26.8 (24.9, 28.5) †84.4 (81.4, 87.4) †70.5 (69.4, 71.4) †00.0 (00.0, 00.0)
1
9
2
h
o
u
r
s
CovEWS 92.5 (91.2, 93.6) 46.9 (42.0, 51.6) 38.5 (35.8, 41.4) 83.7 (80.1, 87.1) 85.7 (84.7, 86.6) 70.5 (65.6, 76.4)
CovEWS (linear) †91.8 (90.7, 93.1) 46.6 (41.9, 51.9) †33.9 (31.3, 36.2) 86.2 (82.9, 90.2) †81.5 (80.3, 82.4) †68.1 (58.6, 73.9)
Liang et al. 2020 †78.2 (75.7, 80.6) †19.6 (16.1, 23.2) †22.8 (20.7, 24.7) †73.1 (68.0, 77.2) †73.2 (72.2, 74.3) †20.6 (11.0, 32.7)
COVER F †62.9 (60.4, 65.3) †07.4 (06.6, 08.1) †14.3 (12.5, 15.8) †65.6 (60.9, 69.5) †57.2 (56.0, 58.4) †08.5 (04.8, 13.6)
SOFA †83.3 (81.6, 85.4) †27.3 (23.4, 31.2) †27.8 (25.6, 30.3) †72.2 (67.8, 76.2) †80.4 (79.4, 81.3) †00.0 (00.0, 00.0)
Yan et al. 2020 †76.9 (74.8, 78.8) 48.7 (46.5, 50.7) †24.1 (22.0, 26.1) †82.2 (78.4, 86.0) †71.5 (70.2, 72.5) †00.0 (00.0, 00.0)
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Table S10: Comparison of CovEWS, CovEWS (linear), COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18] at
various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity and specificity at greater than 95% sensitivity
(Spec.@95%Sens.) for predicting COVID-19 related mortality on the external TriNetX test set. Values are the median and the
95% confidence intervals (CIs, in parentheses) obtained via bootstrap resampling with 200 samples. †= significant at p < 0.05
to CovEWS (one-sided Mann-Whitney-Wilcoxon, Bonferroni corrected). Best results for each metric are highlighted in bold.
External TriNetX Test Set
Model AUC AUPR F1 Sensitivity Specificity Spec.@95%Sens.
1
h
o
u
r
CovEWS 93.6 (92.8, 94.4) 44.8 (40.9, 49.4) 48.1 (45.0, 51.1) 89.8 (86.3, 93.0) 86.8 (86.0, 87.6) 78.8 (76.0, 84.7)
CovEWS (linear) †92.3 (91.3, 93.4) †35.8 (32.3, 39.3) 48.1 (44.5, 51.1) †86.0 (82.3, 89.5) 87.5 (86.7, 88.3) †75.0 (68.6, 81.9)
Liang et al. 2020 †83.6 (81.3, 85.8) †32.5 (27.9, 38.1) †32.6 (29.8, 35.7) †76.7 (72.1, 81.8) †78.8 (77.7, 80.0) †34.4 (19.8, 44.3)
COVER F †73.3 (70.4, 76.1) †15.3 (13.0, 17.7) †22.6 (20.4, 25.0) †70.8 (66.0, 75.7) †67.1 (66.0, 68.4) †13.3 (05.1, 34.0)
SOFA †88.2 (86.1, 90.6) 46.1 (40.7, 50.9) †43.1 (39.9, 46.5) †81.3 (76.9, 85.7) †85.8 (84.9, 86.7) †00.0 (00.0, 00.0)
Yan et al. 2020 †56.6 (55.0, 58.2) 49.0 (47.4, 50.4) †14.4 (12.9, 16.0) 89.4 (86.5, 92.1) †23.6 (22.4, 24.8) †00.0 (00.0, 00.0)
2
h
o
u
r
s
CovEWS 93.6 (92.8, 94.4) 44.8 (40.9, 49.4) 48.1 (45.0, 51.1) 89.8 (86.3, 93.0) 86.8 (86.0, 87.6) 78.8 (76.0, 84.7)
CovEWS (linear) †92.3 (91.3, 93.4) †35.8 (32.3, 39.3) †45.5 (42.0, 48.4) †88.1 (84.9, 91.3) †85.6 (84.7, 86.5) †75.0 (68.6, 81.9)
Liang et al. 2020 †83.6 (81.3, 85.8) †32.5 (27.9, 38.1) †32.6 (29.8, 35.7) †76.7 (72.1, 81.8) †78.8 (77.7, 80.0) †34.4 (19.8, 44.3)
COVER F †73.3 (70.4, 76.1) †15.3 (13.0, 17.7) †22.6 (20.4, 25.0) †70.8 (66.0, 75.7) †67.1 (66.0, 68.4) †13.3 (05.1, 34.0)
SOFA †88.2 (86.1, 90.6) 46.1 (40.7, 50.9) †43.1 (39.9, 46.5) †81.3 (76.9, 85.7) †85.8 (84.9, 86.7) †00.0 (00.0, 00.0)
Yan et al. 2020 †56.6 (55.0, 58.2) 49.0 (47.4, 50.4) †14.4 (12.9, 16.0) 89.4 (86.5, 92.1) †23.6 (22.4, 24.8) †00.0 (00.0, 00.0)
4
h
o
u
r
s
CovEWS 93.6 (92.8, 94.4) 44.8 (40.9, 49.4) 46.8 (43.6, 50.1) 91.0 (87.7, 94.0) 85.7 (84.8, 86.7) 78.8 (76.0, 84.7)
CovEWS (linear) †92.3 (91.3, 93.4) †35.8 (32.3, 39.3) †45.5 (42.0, 48.4) †88.1 (84.9, 91.3) 85.6 (84.7, 86.5) †75.0 (68.6, 81.9)
Liang et al. 2020 †83.6 (81.3, 85.8) †32.5 (27.9, 38.1) †32.6 (29.8, 35.7) †76.7 (72.1, 81.8) †78.8 (77.7, 80.0) †34.4 (19.8, 44.3)
COVER F †73.3 (70.4, 76.1) †15.3 (13.0, 17.7) †22.6 (20.4, 25.0) †70.8 (66.0, 75.7) †67.1 (66.0, 68.4) †13.3 (05.1, 34.0)
SOFA †88.2 (86.1, 90.6) 46.1 (40.7, 50.9) †43.1 (39.9, 46.5) †81.3 (76.9, 85.7) 85.8 (84.9, 86.7) †00.0 (00.0, 00.0)
Yan et al. 2020 †56.6 (55.0, 58.2) 49.0 (47.4, 50.4) †14.4 (12.9, 16.0) †89.4 (86.5, 92.1) †23.6 (22.4, 24.8) †00.0 (00.0, 00.0)
8
h
o
u
r
s
CovEWS 93.6 (92.8, 94.4) 44.8 (40.9, 49.4) 45.6 (42.3, 48.7) 92.4 (88.9, 95.0) 84.6 (83.6, 85.5) 78.8 (76.0, 84.7)
CovEWS (linear) †92.3 (91.3, 93.4) †35.8 (32.3, 39.3) 45.5 (42.0, 48.4) †88.1 (84.9, 91.3) 85.6 (84.7, 86.5) †75.0 (68.6, 81.9)
Liang et al. 2020 †83.6 (81.3, 85.8) †32.5 (27.9, 38.1) †32.6 (29.8, 35.7) †76.7 (72.1, 81.8) †78.8 (77.7, 80.0) †34.4 (19.8, 44.3)
COVER F †73.3 (70.4, 76.1) †15.3 (13.0, 17.7) †22.6 (20.4, 25.0) †70.8 (66.0, 75.7) †67.1 (66.0, 68.4) †13.3 (05.1, 34.0)
SOFA †88.2 (86.1, 90.6) 46.1 (40.7, 50.9) †43.1 (39.9, 46.5) †81.3 (76.9, 85.7) 85.8 (84.9, 86.7) †00.0 (00.0, 00.0)
Yan et al. 2020 †56.6 (55.0, 58.2) 49.0 (47.4, 50.4) †14.4 (12.9, 16.0) †89.4 (86.5, 92.1) †23.6 (22.4, 24.8) †00.0 (00.0, 00.0)
1
6
h
o
u
r
s
CovEWS 92.2 (91.2, 93.2) 45.5 (41.2, 49.9) 46.4 (43.0, 49.5) 92.4 (88.9, 95.0) 81.0 (79.8, 82.0) 74.5 (71.1, 81.1)
CovEWS (linear) †90.7 (89.4, 91.9) †36.4 (33.0, 40.2) 48.4 (45.1, 51.3) †86.0 (82.3, 89.5) 84.4 (83.4, 85.5) †69.5 (62.9, 77.8)
Liang et al. 2020 †82.0 (79.5, 84.4) †34.1 (29.1, 39.3) †35.1 (32.1, 38.1) †76.5 (71.8, 81.2) †76.0 (74.8, 77.4) †30.9 (18.6, 39.7)
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Table S10 cont.
COVER F †71.0 (67.8, 73.8) †16.9 (14.5, 19.6) †24.8 (22.3, 27.3) †70.8 (66.0, 75.7) †63.4 (62.1, 64.9) †11.9 (04.5, 30.1)
SOFA †87.1 (85.0, 89.5) 48.1 (42.1, 53.0) †44.2 (40.9, 47.7) †81.3 (76.9, 85.7) 82.9 (81.9, 84.0) †00.0 (00.0, 00.0)
Yan et al. 2020 †57.1 (55.5, 58.7) 50.1 (48.4, 51.5) †17.7 (15.9, 19.5) †89.4 (86.5, 92.1) †24.6 (23.2, 26.0) †00.0 (00.0, 00.0)
2
4
h
o
u
r
s
CovEWS 92.2 (91.2, 93.2) 45.5 (41.2, 49.9) 45.8 (42.4, 48.9) 92.7 (89.3, 95.2) 80.5 (79.2, 81.5) 74.5 (71.1, 81.1)
CovEWS (linear) †90.7 (89.4, 91.9) †36.4 (33.0, 40.2) 48.4 (45.1, 51.3) †86.0 (82.3, 89.5) 84.4 (83.4, 85.5) †69.5 (62.9, 77.8)
Liang et al. 2020 †82.0 (79.5, 84.4) †34.1 (29.1, 39.3) †35.1 (32.1, 38.1) †76.5 (71.8, 81.2) †76.0 (74.8, 77.4) †30.9 (18.6, 39.7)
COVER F †71.0 (67.8, 73.8) †16.9 (14.5, 19.6) †24.8 (22.3, 27.3) †70.8 (66.0, 75.7) †63.4 (62.1, 64.9) †11.9 (04.5, 30.1)
SOFA †87.1 (85.0, 89.5) 48.1 (42.1, 53.0) †44.2 (40.9, 47.7) †81.3 (76.9, 85.7) 82.9 (81.9, 84.0) †00.0 (00.0, 00.0)
Yan et al. 2020 †57.1 (55.5, 58.7) 50.1 (48.4, 51.5) †17.7 (15.9, 19.5) †89.4 (86.5, 92.1) †24.6 (23.2, 26.0) †00.0 (00.0, 00.0)
4
8
h
o
u
r
s
CovEWS 91.3 (89.9, 92.5) 42.5 (38.3, 47.2) 43.6 (39.9, 46.2) 93.3 (90.3, 96.0) 78.6 (77.4, 79.7) 74.3 (70.0, 80.1)
CovEWS (linear) †90.1 (88.7, 91.3) †34.1 (30.1, 37.8) †42.9 (39.2, 45.7) †86.9 (83.1, 90.2) 80.2 (79.3, 81.5) †72.2 (63.1, 76.2)
Liang et al. 2020 †80.6 (77.6, 83.1) †30.6 (26.2, 35.8) †33.4 (30.2, 36.5) †74.0 (68.5, 78.5) †75.7 (74.3, 77.2) †28.4 (14.1, 37.4)
COVER F †70.5 (67.1, 73.7) †16.2 (13.7, 18.7) †24.5 (22.3, 27.0) †71.5 (66.7, 77.0) †62.6 (61.1, 64.1) †11.6 (04.7, 27.8)
SOFA †86.1 (83.8, 88.6) 45.3 (39.5, 51.6) †42.5 (39.2, 46.3) †80.1 (75.7, 84.9) 82.2 (81.0, 83.1) †00.0 (00.0, 00.0)
Yan et al. 2020 †56.5 (54.9, 58.3) 49.6 (47.9, 51.4) †17.3 (15.5, 19.1) †88.5 (85.4, 91.8) †24.4 (23.0, 25.8) †00.0 (00.0, 00.0)
9
6
h
o
u
r
s
CovEWS (linear) 89.3 (87.7, 90.8) 31.5 (27.6, 35.1) 40.8 (36.7, 43.7) 86.9 (82.7, 90.6) 79.8 (78.6, 80.9) 67.6 (48.9, 73.8)
CovEWS 89.9 (88.4, 91.6) 39.2 (34.5, 44.3) 41.3 (37.4, 44.5) 88.6 (84.3, 91.9) 79.9 (78.7, 81.0) 64.1 (55.5, 72.4)
Liang et al. 2020 †79.6 (76.1, 82.6) †28.0 (22.6, 33.2) †32.5 (28.9, 35.5) †72.2 (66.9, 77.4) †77.1 (75.7, 78.4) †19.6 (13.5, 31.3)
COVER F †70.4 (67.1, 73.6) †15.3 (12.6, 18.0) †23.2 (20.8, 25.7) †65.7 (60.0, 72.2) †66.6 (64.6, 68.1) †13.9 (07.6, 31.0)
SOFA †86.3 (84.0, 88.9) 41.0 (34.7, 46.6) †40.5 (37.5, 44.5) †81.7 (77.2, 87.0) 81.6 (80.4, 82.8) †00.0 (00.0, 00.0)
Yan et al. 2020 †55.3 (53.3, 57.2) 48.3 (46.1, 50.1) †15.9 (13.9, 17.3) †87.0 (82.8, 90.3) †23.7 (22.3, 25.1) †00.0 (00.0, 00.0)
1
9
2
h
o
u
r
s
CovEWS 89.3 (87.5, 91.0) 33.7 (29.0, 38.8) 36.4 (32.6, 40.0) 88.1 (83.7, 92.1) 78.8 (77.4, 79.9) 69.4 (57.6, 75.2)
CovEWS (linear) †87.9 (86.0, 89.8) †26.4 (21.8, 30.9) †34.8 (30.6, 38.0) †87.5 (82.9, 91.7) †77.2 (75.7, 78.7) †61.2 (42.7, 69.8)
Liang et al. 2020 †78.9 (75.3, 82.7) †23.6 (19.1, 29.5) †26.9 (23.1, 31.1) †73.1 (67.0, 79.6) †73.5 (71.9, 75.2) †18.9 (09.7, 39.9)
COVER F †67.8 (64.1, 71.9) †12.8 (10.0, 15.9) †19.5 (16.8, 22.2) †66.7 (60.7, 72.8) †63.0 (61.2, 64.6) †10.8 (03.9, 22.0)
SOFA †85.6 (82.6, 88.0) 34.0 (27.4, 40.5) †34.5 (30.8, 38.6) †78.4 (72.8, 83.5) 80.3 (78.8, 81.8) †00.0 (00.0, 63.1)
Yan et al. 2020 †56.2 (53.9, 58.4) 48.3 (46.0, 50.5) †14.1 (12.3, 16.0) 88.0 (83.3, 92.2) †24.5 (23.0, 26.1) †00.0 (00.0, 00.0)
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Table S11: Comparison of CovEWS, CovEWS (linear), COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18] at
various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity and specificity at greater than 95% sensitivity
(Spec.@95%Sens.) for predicting COVID-19 related mortality on the subgroup of Black or African American patients of the
Optum test set. Values are the median and the 95% confidence intervals (CIs, in parentheses) obtained via bootstrap resampling
with 200 samples. †= significant at p < 0.05 to CovEWS (one-sided Mann-Whitney-Wilcoxon, Bonferroni corrected). Best
results for each metric are highlighted in bold.
Optum Test Set (Black or African American Subgroup)
Model AUC AUPR F1 Sensitivity Specificity Spec.@95%Sens.
1
h
o
u
r
CovEWS 97.6 (96.3, 98.5) 73.2 (65.5, 80.9) 56.1 (51.0, 60.5) 93.7 (89.1, 97.0) 92.7 (91.9, 93.6) 90.9 (69.3, 94.2)
CovEWS (linear) †96.8 (95.2, 98.1) 74.6 (67.1, 80.5) †51.1 (45.6, 55.5) †89.7 (84.7, 94.4) †91.6 (90.6, 92.5) †82.4 (68.9, 90.8)
Liang et al. 2020 †89.4 (86.9, 91.9) †34.3 (27.2, 42.8) †33.9 (30.2, 38.5) †78.6 (72.3, 84.8) †85.3 (84.0, 86.5) †62.8 (36.8, 69.9)
COVER F †83.5 (80.5, 86.1) †19.3 (14.4, 24.9) †24.3 (20.7, 27.9) †78.5 (72.0, 83.6) †76.0 (74.4, 77.6) †48.7 (37.6, 61.1)
SOFA †92.1 (89.7, 93.9) †47.1 (39.1, 55.4) †41.5 (36.4, 47.0) †75.6 (68.9, 81.6) †90.4 (89.4, 91.5) †41.7 (40.1, 79.1)
Yan et al. 2020 †75.5 (72.8, 77.7) †50.2 (47.5, 52.4) †19.3 (16.7, 21.8) †88.9 (83.9, 93.3) †62.1 (60.3, 63.5) †00.0 (00.0, 00.0)
2
h
o
u
r
s
CovEWS 97.2 (95.8, 98.3) 72.0 (63.9, 78.9) 55.8 (50.5, 60.3) 93.1 (88.2, 96.3) 92.7 (91.9, 93.6) 90.4 (66.4, 93.9)
CovEWS (linear) †96.5 (94.7, 97.6) 73.2 (65.8, 79.5) †47.5 (42.0, 51.8) †91.5 (86.8, 95.7) †90.0 (88.9, 90.8) †81.5 (68.5, 90.3)
Liang et al. 2020 †89.0 (86.3, 91.5) †34.5 (27.4, 42.9) †33.9 (30.2, 38.5) †78.6 (72.3, 84.8) †85.3 (84.0, 86.5) †62.2 (30.5, 68.4)
COVER F †83.5 (80.5, 86.1) †19.3 (14.4, 24.9) †24.3 (20.7, 27.9) †78.5 (72.0, 83.6) †76.0 (74.4, 77.6) †48.7 (37.6, 61.1)
SOFA †91.9 (89.2, 93.8) †45.8 (38.2, 54.5) †41.2 (36.4, 46.4) †75.0 (67.8, 81.3) †90.4 (89.4, 91.5) †41.6 (40.1, 79.1)
Yan et al. 2020 †75.2 (72.3, 77.4) †49.9 (47.0, 51.9) †19.2 (16.6, 21.8) †88.3 (82.8, 93.0) †62.1 (60.3, 63.5) †00.0 (00.0, 00.0)
4
h
o
u
r
s
CovEWS 97.3 (96.0, 98.3) 70.9 (62.7, 77.7) 54.3 (48.9, 58.6) 94.0 (90.2, 97.1) 92.2 (91.3, 93.1) 90.7 (69.3, 94.1)
CovEWS (linear) †96.5 (95.0, 97.9) 71.8 (64.0, 79.0) †47.1 (41.8, 51.5) †91.4 (87.6, 95.4) †90.0 (88.9, 90.8) †82.5 (58.9, 90.3)
Liang et al. 2020 †89.2 (86.5, 91.6) †34.5 (27.3, 43.2) †34.2 (30.4, 38.8) †79.9 (73.7, 85.9) †85.3 (84.0, 86.5) †62.2 (30.9, 68.6)
COVER F †83.5 (80.4, 86.0) †19.1 (14.4, 24.8) †24.2 (20.5, 27.9) †78.4 (71.6, 83.5) †76.0 (74.4, 77.6) †48.7 (37.6, 61.1)
SOFA †91.7 (89.1, 93.6) †46.1 (38.0, 54.6) †41.6 (36.8, 47.1) †76.0 (69.3, 82.3) †90.4 (89.4, 91.5) †41.5 (39.9, 78.9)
Yan et al. 2020 †75.2 (72.2, 77.4) †49.8 (47.0, 51.9) †19.0 (16.5, 21.7) †88.3 (82.7, 92.9) †62.1 (60.3, 63.5) †00.0 (00.0, 00.0)
8
h
o
u
r
s
CovEWS 97.4 (96.3, 98.3) 68.9 (61.3, 75.9) 52.1 (46.7, 56.6) 94.5 (90.5, 97.4) 91.3 (90.5, 92.3) 90.7 (77.7, 94.1)
CovEWS (linear) †96.6 (95.0, 97.8) 69.3 (61.0, 77.3) †47.0 (41.9, 51.3) †91.4 (86.8, 95.4) †90.0 (88.9, 90.9) †82.4 (68.9, 90.3)
Liang et al. 2020 †89.3 (86.6, 91.8) †34.3 (27.3, 42.6) †30.5 (27.2, 35.1) †84.3 (79.4, 90.0) †81.3 (80.1, 82.7) †61.8 (30.9, 69.1)
COVER F †83.6 (80.5, 86.1) †19.1 (14.4, 24.9) †24.2 (20.5, 27.9) †78.8 (72.0, 84.0) †76.0 (74.4, 77.6) †48.7 (37.6, 61.1)
SOFA †91.7 (89.3, 93.7) †46.0 (38.1, 54.1) †41.1 (36.2, 47.0) †75.2 (68.4, 81.1) †90.4 (89.4, 91.5) †41.6 (40.1, 78.9)
Yan et al. 2020 †75.7 (73.1, 77.9) †50.3 (47.6, 52.5) †19.3 (16.5, 21.8) †89.4 (84.3, 93.7) †62.1 (60.3, 63.5) †00.0 (00.0, 00.0)
1
6
h
o
u
r
s
CovEWS 96.7 (95.1, 97.6) 66.7 (58.4, 74.8) 51.4 (46.6, 56.6) 94.5 (89.8, 97.8) 89.2 (88.2, 90.5) 88.6 (77.2, 92.4)
CovEWS (linear) †95.8 (94.4, 96.9) 66.7 (57.6, 73.5) †50.3 (45.8, 55.6) †88.8 (83.0, 93.6) 89.9 (88.6, 90.9) †80.0 (69.7, 87.9)
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Table S11 cont.
Liang et al. 2020 †86.9 (83.7, 89.6) †33.1 (25.5, 41.5) †32.8 (29.2, 37.3) †79.4 (73.7, 85.7) †81.2 (79.7, 82.6) †52.5 (28.8, 62.4)
COVER F †81.5 (78.3, 84.4) †20.1 (15.2, 25.8) †26.2 (22.1, 30.2) †68.3 (61.5, 76.1) †78.0 (76.5, 79.6) †43.7 (31.8, 55.8)
SOFA †90.4 (87.6, 92.5) †42.4 (33.6, 50.6) †41.2 (36.7, 47.1) †75.1 (67.8, 80.9) †88.4 (87.2, 89.8) †39.8 (37.7, 76.5)
Yan et al. 2020 †73.6 (70.6, 75.8) †50.2 (46.8, 52.4) †20.8 (18.1, 23.7) †87.8 (82.3, 92.2) †59.4 (57.1, 61.2) †00.0 (00.0, 00.0)
2
4
h
o
u
r
s
CovEWS 96.0 (94.2, 97.2) 63.7 (53.6, 71.4) 48.7 (44.1, 54.2) 92.4 (87.8, 96.3) 88.1 (86.9, 89.4) 83.0 (69.2, 90.0)
CovEWS (linear) †95.3 (93.8, 96.6) 64.0 (54.7, 72.0) 49.1 (44.3, 53.8) †89.1 (83.7, 94.6) 88.9 (87.6, 90.2) †76.9 (59.1, 87.7)
Liang et al. 2020 †85.5 (82.2, 88.4) †33.5 (25.3, 42.3) †32.5 (28.1, 36.9) †77.3 (71.2, 83.7) †80.9 (79.6, 82.4) †44.4 (25.0, 57.4)
COVER F †81.2 (77.9, 84.1) †20.3 (15.3, 25.9) †26.4 (22.4, 30.1) †64.7 (57.9, 71.9) †79.0 (77.5, 80.7) †42.8 (30.9, 54.9)
SOFA †89.0 (85.7, 91.5) †40.9 (32.8, 48.6) †40.1 (35.3, 44.7) †72.0 (64.5, 79.3) 88.0 (86.8, 89.5) †39.0 (00.0, 41.1)
Yan et al. 2020 †72.4 (69.0, 75.1) †49.6 (46.3, 52.2) †20.6 (17.9, 23.5) †86.5 (80.7, 91.6) †58.5 (56.1, 60.1) †00.0 (00.0, 00.0)
4
8
h
o
u
r
s
CovEWS 95.3 (93.4, 96.5) 60.7 (51.4, 68.9) 47.1 (41.8, 51.9) 92.6 (88.2, 96.4) 87.0 (85.7, 88.2) 81.3 (60.9, 88.0)
CovEWS (linear) †94.5 (92.9, 95.8) 61.6 (52.1, 68.9) †42.1 (37.6, 47.2) †88.7 (82.6, 93.4) †85.1 (83.7, 86.5) †75.7 (61.8, 83.6)
Liang et al. 2020 †85.3 (82.5, 88.1) †31.1 (24.3, 38.0) †31.0 (26.9, 35.7) †75.7 (68.7, 82.0) †79.8 (78.1, 81.6) †46.6 (26.9, 61.0)
COVER F †81.1 (77.6, 83.8) †21.2 (15.8, 27.0) †26.3 (22.2, 30.6) †64.5 (57.1, 72.6) †78.8 (77.2, 80.3) †43.1 (30.0, 54.2)
SOFA †87.3 (84.0, 90.1) †38.7 (29.6, 46.4) †36.8 (31.9, 42.4) †66.8 (59.1, 73.9) 87.4 (86.2, 88.8) †38.0 (00.0, 39.8)
Yan et al. 2020 †72.3 (69.4, 75.0) †50.1 (47.0, 52.8) †20.5 (17.9, 23.2) †87.7 (82.3, 93.0) †56.9 (54.5, 58.9) †00.0 (00.0, 00.0)
9
6
h
o
u
r
s
CovEWS 94.7 (92.3, 96.1) 59.5 (48.0, 67.6) 41.8 (36.1, 46.2) 87.0 (80.5, 92.8) 85.9 (84.6, 87.6) 74.8 (54.1, 85.2)
CovEWS (linear) †93.8 (91.9, 95.5) 61.3 (50.6, 69.3) †37.4 (33.0, 42.5) 87.0 (80.6, 93.2) †83.1 (81.4, 84.6) †69.5 (59.9, 79.7)
Liang et al. 2020 †85.3 (82.1, 87.9) †26.8 (19.5, 33.7) †26.3 (22.5, 30.6) †76.7 (69.7, 83.6) †75.3 (73.5, 77.2) †56.6 (39.3, 64.1)
COVER F †80.4 (76.5, 83.7) †19.9 (14.0, 26.0) †23.9 (18.9, 28.1) †62.3 (52.9, 70.5) †78.1 (76.5, 79.9) †42.0 (28.9, 52.9)
SOFA †86.9 (82.8, 90.0) †36.1 (27.2, 44.5) †35.3 (30.1, 40.1) †67.2 (58.2, 75.8) 86.9 (85.6, 88.4) †37.0 (34.3, 39.1)
Yan et al. 2020 †71.3 (67.8, 74.5) †49.2 (45.6, 52.3) †19.1 (15.9, 21.9) 86.8 (81.1, 92.9) †55.9 (53.3, 57.7) †00.0 (00.0, 00.0)
1
9
2
h
o
u
r
s
CovEWS 94.1 (92.1, 95.5) 51.8 (40.1, 62.8) 40.0 (34.0, 45.3) 85.3 (78.2, 91.9) 85.5 (83.8, 87.0) 78.9 (59.4, 83.8)
CovEWS (linear) †93.1 (90.8, 94.9) 53.2 (41.4, 64.1) †35.9 (30.5, 40.8) 89.0 (82.6, 94.5) †81.7 (79.8, 83.7) †67.6 (57.1, 80.6)
COVER F †80.9 (76.4, 84.3) †18.1 (13.6, 24.4) †24.0 (18.0, 28.8) †62.4 (51.9, 71.4) †78.4 (76.5, 80.5) †42.6 (25.3, 53.8)
Liang et al. 2020 †82.7 (79.1, 85.6) †25.5 (17.2, 32.6) †26.6 (22.1, 31.0) †74.2 (65.6, 81.4) †77.1 (75.2, 79.0) †39.4 (14.4, 61.2)
SOFA †83.4 (79.7, 88.1) †30.1 (21.4, 40.7) †31.4 (25.2, 36.7) †62.8 (52.2, 74.4) 85.7 (84.2, 87.4) †36.7 (00.0, 39.3)
Yan et al. 2020 †71.9 (68.2, 74.8) †49.6 (46.1, 52.9) †19.1 (15.3, 22.4) 87.6 (81.4, 93.5) †56.3 (53.8, 58.4) †00.0 (00.0, 00.0)
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Table S12: Comparison of CovEWS, CovEWS (linear), COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18] at
various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity and specificity at greater than 95% sensitivity
(Spec.@95%Sens.) for predicting COVID-19 related mortality on the subgroup of Hispanic patients of the Optum test set.
Values are the median and the 95% confidence intervals (CIs, in parentheses) obtained via bootstrap resampling with 200
samples. †= significant at p < 0.05 to CovEWS (one-sided Mann-Whitney-Wilcoxon, Bonferroni corrected). Best results for
each metric are highlighted in bold.
Optum Test Set (Hispanic Subgroup)
Model AUC AUPR F1 Sensitivity Specificity Spec.@95%Sens.
1
h
o
u
r
CovEWS (linear) 98.7 (97.9, 99.3) 75.0 (62.0, 87.0) 51.3 (40.6, 59.7) 92.7 (86.0, 100.0) 94.8 (93.6, 95.8) 92.8 (87.2, 97.3)
CovEWS 98.3 (97.0, 99.1) 71.2 (58.9, 82.6) 49.4 (38.2, 57.7) 92.7 (83.7, 100.0) 94.2 (93.1, 95.3) 85.9 (83.1, 97.8)
Liang et al. 2020 †95.2 (92.9, 96.8) †43.8 (28.4, 58.4) †29.5 (22.0, 36.2) †85.5 (75.0, 93.8) †87.8 (86.5, 89.4) †79.1 (74.7, 86.5)
COVER F †85.4 (81.7, 89.0) †11.6 (07.5, 17.1) †16.7 (11.1, 21.6) †73.1 (60.5, 84.6) †78.3 (75.8, 80.4) †56.4 (43.1, 73.9)
SOFA †91.3 (85.9, 95.9) †46.5 (32.7, 60.5) †29.3 (22.2, 35.2) †89.1 (79.5, 97.6) †87.2 (85.3, 88.7) †00.0 (00.0, 87.4)
Yan et al. 2020 †71.7 (67.0, 75.4) †47.6 (42.6, 51.4) †10.7 (07.2, 13.6) †89.1 (80.0, 96.2) †54.1 (51.5, 56.1) †00.0 (00.0, 54.4)
2
h
o
u
r
s
CovEWS (linear) 98.6 (97.8, 99.3) 74.4 (61.0, 86.7) 48.8 (37.6, 57.4) 95.0 (87.3, 100.0) 93.9 (92.7, 95.0) 93.1 (87.2, 96.3)
CovEWS 98.3 (97.2, 99.1) 71.5 (58.2, 83.2) 49.4 (38.2, 57.7) 92.7 (83.7, 100.0) 94.2 (93.1, 95.3) 86.1 (83.3, 97.4)
Liang et al. 2020 †95.2 (92.9, 96.8) †43.8 (28.4, 58.4) †29.5 (22.0, 36.2) †85.5 (75.0, 93.8) †87.8 (86.5, 89.4) †79.1 (74.7, 86.5)
COVER F †85.4 (81.7, 89.0) †11.6 (07.5, 17.1) †16.9 (11.8, 21.2) †88.6 (80.0, 96.0) †73.4 (71.2, 75.5) †56.4 (43.1, 73.9)
SOFA †92.2 (86.8, 96.0) †46.5 (33.2, 60.8) †29.3 (22.2, 35.2) †89.1 (79.5, 97.6) †87.2 (85.3, 88.7) †00.0 (00.0, 87.4)
Yan et al. 2020 †72.7 (67.2, 76.0) †48.6 (43.3, 51.6) †11.0 (07.4, 13.9) †91.3 (81.5, 97.7) †54.1 (51.5, 56.1) †00.0 (00.0, 54.9)
4
h
o
u
r
s
CovEWS (linear) 98.7 (97.8, 99.2) 72.6 (58.1, 85.5) 48.7 (37.6, 57.4) 95.0 (87.3, 100.0) 93.9 (92.7, 95.0) 93.1 (87.2, 96.8)
CovEWS 98.4 (97.4, 99.0) 67.6 (52.9, 78.8) 47.2 (36.7, 55.5) 94.4 (88.4, 100.0) 93.5 (92.3, 94.7) 90.6 (84.4, 97.4)
Liang et al. 2020 †94.8 (92.5, 96.7) †42.3 (27.4, 57.5) †29.5 (22.0, 36.2) †85.5 (75.0, 93.8) †87.8 (86.5, 89.4) †78.9 (63.3, 86.5)
COVER F †85.4 (81.7, 89.0) †11.6 (07.5, 17.1) †16.9 (11.8, 21.2) †88.6 (80.0, 96.0) †73.4 (71.2, 75.5) †56.4 (43.1, 73.9)
SOFA †91.3 (85.8, 95.8) †43.9 (30.4, 58.7) †29.3 (22.2, 35.2) †89.1 (79.5, 97.6) †87.2 (85.3, 88.7) †00.0 (00.0, 87.4)
Yan et al. 2020 †72.7 (67.2, 76.0) †48.6 (43.3, 51.6) †11.0 (07.4, 13.9) †91.3 (81.5, 97.7) †54.1 (51.5, 56.1) †00.0 (00.0, 55.0)
8
h
o
u
r
s
CovEWS 98.4 (97.5, 99.1) 65.3 (51.0, 76.6) 45.7 (35.6, 53.7) 95.0 (87.0, 100.0) 93.1 (91.7, 94.3) 93.5 (84.4, 97.6)
CovEWS (linear) 98.6 (97.8, 99.2) 69.7 (53.9, 82.7) 48.7 (37.6, 57.4) 95.0 (87.3, 100.0) 93.9 (92.7, 95.0) 93.2 (87.2, 97.4)
Liang et al. 2020 †95.2 (93.0, 96.8) †42.1 (27.6, 57.7) †29.5 (22.0, 36.2) †85.5 (75.0, 93.8) †87.8 (86.5, 89.4) †79.7 (76.3, 86.5)
COVER F †85.4 (81.7, 89.0) †11.6 (07.5, 17.1) †16.9 (11.8, 21.2) †88.6 (80.0, 96.0) †73.4 (71.2, 75.5) †56.4 (43.1, 73.9)
SOFA †91.1 (85.7, 95.7) †41.3 (28.4, 56.1) †29.3 (22.2, 35.2) †89.1 (79.5, 97.6) †87.2 (85.3, 88.7) †00.0 (00.0, 87.4)
Yan et al. 2020 †73.6 (69.6, 76.5) †49.5 (45.2, 52.3) †11.2 (07.5, 14.3) †93.0 (85.0, 98.2) †54.1 (51.5, 56.1) †00.0 (00.0, 55.6)
1
6
h
o
u
r
s
CovEWS (linear) 97.9 (96.8, 98.7) 67.1 (48.5, 79.0) 50.1 (40.0, 59.5) 91.1 (81.2, 98.0) 93.3 (91.6, 94.4) 89.2 (83.9, 96.2)
CovEWS 97.1 (95.3, 98.4) 61.7 (46.1, 72.7) 46.7 (34.6, 54.5) 92.7 (85.0, 100.0) 91.7 (89.9, 93.1) 83.0 (71.0, 96.1)
4
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Liang et al. 2020 †94.2 (91.9, 96.1) †41.7 (27.1, 56.9) †31.0 (23.2, 38.8) †87.5 (76.9, 95.8) †84.7 (82.8, 86.7) †75.7 (71.3, 85.5)
COVER F †82.7 (78.3, 86.8) †12.1 (07.8, 18.4) †18.0 (11.8, 23.3) †72.7 (59.6, 84.1) †74.2 (71.3, 76.5) †51.6 (38.8, 69.5)
SOFA †89.2 (84.0, 94.2) †38.6 (25.2, 53.3) †30.0 (22.9, 36.7) †84.8 (75.0, 94.1) †84.6 (82.3, 86.5) †00.0 (00.0, 68.7)
Yan et al. 2020 †73.6 (68.5, 76.9) †49.6 (44.2, 52.8) †14.4 (09.7, 18.3) †91.1 (81.4, 97.2) †55.9 (53.4, 58.8) †00.0 (00.0, 56.6)
2
4
h
o
u
r
s
CovEWS 96.5 (95.0, 98.0) 55.1 (40.8, 70.5) 43.9 (33.5, 52.0) 90.2 (81.8, 98.1) 90.8 (89.2, 92.4) 83.8 (72.5, 93.4)
CovEWS (linear) 96.7 (94.9, 98.2) 62.1 (46.2, 76.7) 48.5 (38.3, 57.6) †86.7 (75.0, 95.5) 93.2 (91.6, 94.4) †82.9 (72.3, 92.7)
Liang et al. 2020 †93.5 (90.4, 95.9) †40.5 (27.2, 54.6) †37.0 (27.3, 46.2) †84.5 (73.6, 93.9) †88.8 (87.2, 90.7) †74.4 (45.2, 85.6)
COVER F †82.0 (77.4, 86.4) †11.9 (07.6, 17.7) †18.1 (13.0, 23.1) †87.9 (78.8, 95.7) †68.2 (65.5, 70.5) †50.6 (38.0, 68.4)
SOFA †88.3 (82.4, 93.5) †37.5 (25.1, 52.3) †28.3 (20.8, 35.8) †80.2 (68.0, 90.9) †84.1 (81.8, 86.1) †00.0 (00.0, 66.8)
Yan et al. 2020 †74.1 (69.1, 77.1) †50.5 (45.8, 53.7) †14.6 (09.8, 18.6) 92.9 (84.4, 98.1) †55.5 (52.8, 58.3) †00.0 (00.0, 57.6)
4
8
h
o
u
r
s
CovEWS (linear) 97.2 (96.0, 98.3) 57.5 (42.2, 75.0) 46.2 (35.0, 54.8) 90.3 (82.1, 97.7) 91.5 (89.6, 92.9) 89.2 (80.7, 94.3)
CovEWS 96.3 (94.7, 97.7) 48.5 (34.3, 62.5) 41.3 (29.9, 50.0) 87.9 (78.7, 96.2) 89.6 (87.4, 91.4) 83.6 (80.1, 90.6)
Liang et al. 2020 †92.8 (89.7, 95.3) †43.2 (27.8, 57.4) †35.4 (25.9, 44.3) †80.0 (67.4, 90.9) †88.2 (86.6, 90.2) †73.5 (64.1, 81.5)
COVER F †82.2 (77.7, 86.6) †12.5 (08.0, 18.7) †18.5 (12.7, 25.6) †53.4 (40.0, 67.9) †82.2 (79.4, 84.6) †50.7 (37.2, 68.2)
SOFA †87.7 (81.8, 92.7) †34.9 (22.8, 50.7) †28.2 (21.2, 35.7) †81.5 (69.6, 93.0) †83.2 (80.5, 85.4) †00.0 (00.0, 65.7)
Yan et al. 2020 †74.3 (70.5, 77.9) 50.7 (46.5, 53.8) †15.1 (10.3, 19.7) 92.5 (85.2, 100.0) †55.8 (53.3, 58.9) †00.0 (00.0, 58.0)
9
6
h
o
u
r
s
CovEWS (linear) 95.8 (94.0, 97.4) 49.0 (30.0, 66.8) 42.6 (31.0, 51.9) 86.7 (74.5, 95.4) 90.0 (87.7, 92.0) 85.9 (71.0, 90.4)
CovEWS 94.2 (91.2, 96.6) 40.1 (24.5, 56.3) 40.6 (28.9, 48.9) 86.0 (75.0, 95.1) 89.1 (87.1, 91.3) 80.0 (52.0, 88.5)
Liang et al. 2020 †91.3 (88.1, 93.8) †33.7 (21.5, 48.5) †34.1 (23.4, 44.8) †64.6 (48.8, 80.0) 90.2 (88.2, 92.1) †76.9 (64.5, 82.8)
COVER F †81.0 (75.5, 85.6) †12.6 (07.5, 19.0) †19.3 (12.3, 27.6) †50.0 (35.7, 64.9) †83.6 (80.6, 86.1) †47.7 (34.2, 66.1)
SOFA †86.1 (78.9, 92.1) †29.8 (18.7, 44.6) †27.3 (19.7, 35.7) †79.6 (65.8, 90.9) †81.4 (78.6, 84.0) †00.0 (00.0, 63.9)
Yan et al. 2020 †74.1 (69.0, 78.5) 50.2 (44.5, 54.6) †16.3 (10.7, 21.7) 91.5 (82.0, 97.9) †57.3 (54.4, 60.5) †00.0 (00.0, 59.3)
1
9
2
h
o
u
r
s
CovEWS (linear) 95.8 (93.9, 97.5) 42.7 (25.2, 60.8) 40.1 (26.9, 51.7) 94.0 (84.4, 100.0) 87.3 (84.0, 89.7) 85.5 (75.7, 93.3)
CovEWS 94.5 (91.4, 96.3) 38.8 (22.0, 55.5) 39.2 (27.8, 50.3) 90.5 (75.9, 100.0) 87.5 (84.8, 90.1) 80.3 (76.5, 90.6)
Liang et al. 2020 †87.1 (82.0, 91.4) †23.0 (11.6, 37.3) †27.5 (17.8, 37.0) †70.0 (53.1, 84.0) †84.8 (81.5, 87.3) †64.1 (53.1, 73.6)
COVER F †79.8 (74.0, 85.6) †11.7 (06.6, 18.4) †17.7 (10.1, 24.1) †75.0 (57.9, 89.6) †68.8 (64.5, 72.2) †45.5 (32.7, 66.7)
SOFA †85.8 (77.1, 92.8) †23.4 (12.5, 37.8) †25.4 (17.5, 34.3) †80.6 (62.8, 93.1) †79.9 (76.6, 82.5) †00.0 (00.0, 62.9)
Yan et al. 2020 †76.1 (69.2, 79.6) 52.3 (45.3, 55.5) †16.7 (10.6, 22.8) 94.6 (82.1, 100.0) †57.7 (54.0, 60.7) †00.0 (00.0, 59.8)
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Table S13: Comparison of CovEWS, CovEWS (linear), COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18] at
various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity and specificity at greater than 95% sensitivity
(Spec.@95%Sens.) for predicting COVID-19 related mortality on the subgroup of Asian patients of the Optum test set. Values
are the median and the 95% confidence intervals (CIs, in parentheses) obtained via bootstrap resampling with 200 samples. †=
significant at p < 0.05 to CovEWS (one-sided Mann-Whitney-Wilcoxon, Bonferroni corrected). Best results for each metric are
highlighted in bold.
Optum Test Set (Asian Subgroup)
Model AUC AUPR F1 Sensitivity Specificity Spec.@95%Sens.
1
h
o
u
r
CovEWS (linear) 99.2 (98.3, 99.7) 78.7 (58.8, 94.1) 58.3 (42.3, 68.1) 100.0 (100.0, 100.0) 93.5 (90.5, 95.6) 97.9 (92.9, 99.4)
CovEWS 99.2 (98.2, 99.7) 81.7 (62.3, 93.9) 51.3 (38.4, 62.7) 100.0 (100.0, 100.0) 91.7 (88.8, 93.9) 96.9 (93.2, 99.4)
SOFA †96.8 (94.7, 98.3) †51.6 (30.8, 75.3) †42.1 (27.9, 54.2) 100.0 (100.0, 100.0) †87.3 (84.1, 90.3) †87.6 (84.7, 92.4)
Yan et al. 2020 †79.2 (73.0, 82.6) †53.6 (46.5, 57.4) †19.3 (13.2, 26.0) †95.6 (84.2, 100.0) †62.3 (58.3, 66.4) †60.3 (00.0, 65.8)
COVER F †87.7 (76.4, 95.1) †20.5 (09.9, 37.5) †28.8 (17.5, 39.7) †85.2 (63.6, 100.0) †84.3 (80.6, 87.6) †39.5 (19.8, 86.9)
Liang et al. 2020 †89.0 (77.8, 95.8) †02.2 (01.2, 04.0) †05.9 (03.2, 08.9) †78.9 (60.0, 95.5) †00.4 (00.0, 01.2) †00.0 (00.0, 02.5)
2
h
o
u
r
s
CovEWS (linear) 99.1 (98.1, 99.7) 73.6 (51.6, 91.1) 53.9 (39.6, 64.4) 100.0 (100.0, 100.0) 92.2 (89.3, 94.5) 97.9 (92.9, 99.4)
CovEWS 99.1 (98.1, 99.7) 80.0 (60.5, 93.4) 51.3 (38.4, 62.7) 100.0 (100.0, 100.0) 91.7 (88.8, 93.9) 96.5 (93.2, 99.4)
SOFA †96.8 (94.7, 98.3) †52.3 (30.8, 75.3) †42.1 (27.9, 54.2) 100.0 (100.0, 100.0) †87.3 (84.1, 90.3) †87.6 (84.7, 92.4)
Yan et al. 2020 †79.2 (73.0, 82.6) †53.6 (46.5, 57.4) †19.3 (13.2, 26.0) †95.6 (84.2, 100.0) †62.3 (58.3, 66.4) †60.3 (00.0, 65.8)
COVER F †87.7 (76.4, 95.1) †20.5 (09.9, 37.5) †28.8 (17.5, 39.7) †85.2 (63.6, 100.0) †84.3 (80.6, 87.6) †39.5 (19.8, 86.9)
Liang et al. 2020 †89.0 (77.8, 95.8) †02.2 (01.2, 04.0) †05.9 (03.2, 08.9) †78.9 (60.0, 95.5) †00.4 (00.0, 01.2) †00.0 (00.0, 02.5)
4
h
o
u
r
s
CovEWS (linear) 99.2 (98.3, 99.7) 73.6 (53.5, 91.8) 53.9 (39.6, 64.4) 100.0 (100.0, 100.0) 92.2 (89.3, 94.5) 98.5 (97.1, 99.4)
CovEWS 99.2 (98.5, 99.7) 80.3 (61.0, 94.6) 48.6 (36.4, 59.6) 100.0 (100.0, 100.0) 90.6 (87.6, 93.1) 97.7 (95.7, 99.2)
SOFA †96.8 (94.9, 98.2) †50.8 (31.5, 73.9) †42.1 (27.9, 54.2) 100.0 (100.0, 100.0) †87.3 (84.1, 90.3) †87.9 (85.0, 93.2)
Yan et al. 2020 †79.2 (73.0, 82.6) †53.6 (46.5, 57.4) †19.3 (13.2, 26.0) †95.6 (84.2, 100.0) †62.3 (58.3, 66.4) †60.3 (00.0, 65.8)
COVER F †87.7 (76.4, 95.1) †20.5 (09.9, 37.5) †28.8 (17.5, 39.7) †85.2 (63.6, 100.0) †84.3 (80.6, 87.6) †39.5 (19.8, 86.9)
Liang et al. 2020 †89.0 (77.7, 95.9) †07.1 (01.2, 17.8) †05.9 (03.2, 08.9) †78.9 (60.0, 95.5) †00.4 (00.0, 01.2) †00.0 (00.0, 01.1)
8
h
o
u
r
s
CovEWS (linear) 99.0 (98.1, 99.6) 67.6 (45.1, 88.6) 53.9 (39.6, 64.4) 100.0 (100.0, 100.0) 92.2 (89.3, 94.5) 98.4 (97.1, 99.4)
CovEWS 99.1 (98.2, 99.7) 75.6 (54.2, 91.7) 47.4 (35.3, 58.0) 100.0 (100.0, 100.0) 90.0 (87.0, 92.6) 97.6 (95.7, 98.8)
SOFA †96.6 (94.7, 98.1) †49.2 (29.6, 72.1) †42.1 (28.2, 54.2) 100.0 (100.0, 100.0) †87.3 (84.1, 90.3) †87.9 (85.0, 93.2)
Yan et al. 2020 †79.2 (73.0, 82.6) †53.6 (46.5, 57.4) †19.3 (13.2, 26.0) †95.6 (84.2, 100.0) †62.4 (58.3, 66.4) †60.3 (00.0, 65.8)
COVER F †87.7 (76.4, 95.1) †20.5 (09.9, 37.5) †28.8 (17.5, 39.7) †85.2 (63.6, 100.0) †84.3 (80.6, 87.6) †39.5 (19.8, 86.9)
Liang et al. 2020 †88.9 (77.5, 95.7) †07.1 (01.2, 17.8) †05.9 (03.2, 08.9) †78.9 (60.0, 95.5) †00.4 (00.0, 01.2) †00.0 (00.0, 01.9)
1
6
h
o
u
r
s
CovEWS (linear) 98.7 (97.6, 99.5) 74.3 (54.2, 91.1) 58.3 (43.6, 70.3) 100.0 (100.0, 100.0) 91.8 (88.3, 94.3) 97.4 (95.5, 98.9)
CovEWS 98.6 (97.4, 99.4) 72.0 (51.0, 89.5) 54.7 (40.6, 68.4) 100.0 (100.0, 100.0) 90.6 (87.5, 93.5) 95.6 (91.0, 98.6)
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SOFA †96.1 (93.7, 97.8) †52.1 (31.4, 74.8) †44.9 (30.6, 57.0) 100.0 (100.0, 100.0) †85.6 (81.7, 88.7) †85.8 (81.9, 91.9)
Yan et al. 2020 †75.8 (69.2, 79.9) †53.5 (46.4, 57.3) †19.2 (13.7, 26.7) †95.2 (83.3, 100.0) †56.3 (51.3, 60.9) †53.3 (00.0, 60.2)
COVER F †86.0 (73.8, 94.6) †21.6 (10.7, 41.6) †30.5 (19.0, 43.0) †84.2 (62.5, 100.0) †82.3 (77.8, 86.3) †27.2 (19.0, 84.3)
Liang et al. 2020 †86.9 (73.7, 94.5) †08.0 (01.5, 19.1) †08.0 (04.6, 12.1) †90.0 (71.4, 100.0) †00.6 (00.0, 01.6) †00.0 (00.0, 03.5)
2
4
h
o
u
r
s
CovEWS (linear) 98.3 (96.7, 99.3) 70.7 (48.1, 87.6) 52.9 (37.3, 64.8) 100.0 (100.0, 100.0) 90.8 (87.2, 93.3) 95.1 (90.7, 98.4)
CovEWS 98.1 (96.3, 99.2) 71.6 (51.8, 87.3) 49.2 (33.9, 62.4) 100.0 (100.0, 100.0) 89.2 (85.8, 92.5) 92.3 (88.6, 97.7)
SOFA †94.9 (91.5, 97.3) †41.3 (22.6, 65.4) †40.0 (27.0, 51.7) †95.2 (80.0, 100.0) †85.6 (81.9, 89.0) †81.3 (63.3, 91.2)
COVER F †87.3 (73.2, 94.2) †19.3 (07.5, 39.2) †27.9 (14.1, 40.8) †83.0 (54.1, 100.0) †82.7 (78.3, 86.7) †24.9 (18.4, 84.4)
Liang et al. 2020 †89.0 (84.1, 93.3) †02.2 (01.3, 03.5) †07.2 (03.9, 11.4) †93.8 (77.8, 100.0) †00.9 (00.0, 02.0) †00.0 (00.0, 06.2)
Yan et al. 2020 †72.2 (64.1, 78.2) †50.5 (42.2, 56.1) †17.4 (11.8, 24.9) †90.9 (76.4, 100.0) †53.9 (48.9, 58.8) †00.0 (00.0, 57.3)
4
8
h
o
u
r
s
CovEWS (linear) 98.2 (96.6, 99.4) 69.0 (38.4, 88.5) 45.1 (29.1, 58.5) 100.0 (100.0, 100.0) 89.4 (86.0, 92.4) 93.0 (89.3, 98.7)
CovEWS 98.1 (96.3, 99.2) 69.2 (46.5, 86.5) 40.5 (26.4, 53.7) 100.0 (100.0, 100.0) 87.1 (83.0, 90.4) 92.5 (88.9, 96.9)
SOFA †94.2 (89.0, 97.5) †34.0 (15.7, 67.0) †33.0 (19.4, 46.8) †88.1 (63.1, 100.0) †85.3 (81.1, 88.7) †67.9 (62.8, 93.1)
COVER F †84.3 (68.5, 94.0) †14.2 (05.2, 36.7) †21.3 (09.3, 32.8) †77.4 (42.9, 100.0) †82.1 (77.3, 86.3) †23.7 (17.4, 84.0)
Liang et al. 2020 †89.5 (82.9, 94.0) †01.8 (00.9, 03.0) †05.7 (02.9, 09.7) †91.7 (72.7, 100.0) †00.9 (00.0, 02.2) †00.0 (00.0, 05.9)
Yan et al. 2020 †71.6 (61.2, 78.2) †49.0 (37.3, 55.2) †15.2 (09.0, 22.2) †88.2 (66.7, 100.0) †54.3 (48.9, 59.5) †00.0 (00.0, 56.7)
9
6
h
o
u
r
s
CovEWS 97.5 (94.8, 99.0) 57.0 (25.7, 80.9) 37.7 (23.5, 52.4) 100.0 (100.0, 100.0) 87.6 (82.6, 90.7) 90.8 (86.1, 97.6)
CovEWS (linear) †96.1 (91.0, 99.2) 52.9 (24.0, 77.3) 35.9 (18.6, 50.0) †86.7 (54.5, 100.0) 89.2 (84.7, 91.8) †82.0 (73.8, 98.7)
COVER F †89.2 (80.7, 95.6) †13.2 (03.1, 36.6) †15.9 (03.6, 29.2) †75.0 (25.0, 100.0) †82.5 (77.3, 87.0) †77.3 (70.7, 87.6)
Liang et al. 2020 †88.3 (78.4, 94.6) †01.3 (00.5, 02.5) †04.0 (01.4, 07.7) †85.7 (57.0, 100.0) †00.7 (00.0, 01.8) †00.7 (00.0, 10.3)
SOFA †90.5 (76.7, 97.1) †28.1 (10.8, 57.0) †30.6 (15.9, 44.8) †85.7 (54.5, 100.0) †86.2 (82.2, 89.7) †00.0 (00.0, 92.1)
Yan et al. 2020 †65.7 (53.0, 76.8) †43.2 (30.0, 53.5) †12.6 (06.5, 19.6) †78.6 (53.2, 100.0) †53.1 (47.4, 58.4) †00.0 (00.0, 52.7)
1
9
2
h
o
u
r
s
CovEWS 98.4 (95.6, 99.9) 62.8 (15.0, 96.6) 26.1 (09.3, 40.8) 100.0 (100.0, 100.0) 87.2 (82.2, 90.8) 96.1 (93.1, 99.6)
CovEWS (linear) 98.8 (95.1, 100.0) 77.0 (19.8, 100.0) 25.8 (08.7, 41.7) 100.0 (100.0, 100.0) 86.8 (81.6, 90.7) †93.8 (88.7, 100.0)
SOFA †95.8 (92.1, 98.5) †19.5 (06.0, 39.1) †12.5 (04.1, 21.1) 100.0 (100.0, 100.0) †67.2 (62.4, 73.4) †92.0 (88.5, 97.0)
COVER F †89.7 (79.4, 98.4) †15.8 (02.1, 52.9) †16.0 (03.8, 29.0) †83.3 (33.3, 100.0) †82.4 (77.2, 87.2) †77.3 (69.4, 97.1)
Liang et al. 2020 †89.0 (75.7, 97.0) †01.1 (00.3, 02.3) †00.0 (00.0, 00.0) †00.0 (00.0, 00.0) †55.0 (48.5, 61.2) †03.7 (01.2, 16.1)
Yan et al. 2020 †71.1 (57.9, 78.6) †48.7 (34.1, 54.9) †11.7 (05.7, 19.1) †90.0 (62.5, 100.0) †52.6 (46.4, 59.3) †00.0 (00.0, 57.2)
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Table S14: Comparison of CovEWS, CovEWS (linear), COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18] at
various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity and specificity at greater than 95% sensitivity
(Spec.@95%Sens.) for predicting COVID-19 related mortality on the subgroup of Caucasian patients of the Optum test set.
Values are the median and the 95% confidence intervals (CIs, in parentheses) obtained via bootstrap resampling with 200
samples. †= significant at p < 0.05 to CovEWS (one-sided Mann-Whitney-Wilcoxon, Bonferroni corrected). Best results for
each metric are highlighted in bold.
Optum Test Set (Caucasian Subgroup)
Model AUC AUPR F1 Sensitivity Specificity Spec.@95%Sens.
1
h
o
u
r
CovEWS 96.7 (96.2, 97.4) 67.5 (63.1, 72.2) 56.9 (53.6, 60.0) 91.3 (88.6, 94.1) 90.8 (90.0, 91.5) 87.3 (82.7, 89.4)
CovEWS (linear) 96.8 (96.1, 97.3) 71.7 (66.8, 75.3) †54.6 (51.6, 57.2) †89.8 (87.1, 92.3) †90.4 (89.8, 91.1) †85.3 (81.9, 87.8)
COVER F †65.2 (62.7, 67.7) †08.8 (07.8, 09.7) †16.9 (15.5, 18.3) †74.9 (70.9, 78.9) †51.2 (50.0, 52.5) †21.0 (12.8, 32.8)
Liang et al. 2020 †82.1 (80.1, 84.4) †04.1 (03.6, 05.2) †02.3 (01.1, 03.7) †03.0 (01.5, 04.7) †88.7 (88.0, 89.5) †00.4 (00.3, 00.6)
SOFA †90.3 (88.6, 91.6) †48.5 (44.0, 52.8) †49.2 (45.8, 51.8) †77.6 (73.6, 81.1) †90.2 (89.5, 90.8) †00.0 (00.0, 00.0)
Yan et al. 2020 †82.3 (80.2, 84.0) †54.1 (51.5, 56.2) †38.9 (36.3, 41.4) †81.5 (77.5, 84.9) †83.2 (82.2, 84.0) †00.0 (00.0, 00.0)
2
h
o
u
r
s
CovEWS 96.8 (96.3, 97.4) 67.1 (62.9, 71.8) 56.8 (53.4, 59.9) 91.3 (88.6, 94.1) 90.8 (90.0, 91.5) 87.4 (84.0, 89.5)
CovEWS (linear) †96.7 (96.1, 97.2) 70.9 (65.9, 74.4) †51.0 (48.0, 53.9) 91.6 (89.1, 94.1) †88.4 (87.7, 89.2) †84.7 (81.9, 87.6)
COVER F †65.2 (62.7, 67.7) †08.8 (07.8, 09.7) †16.9 (15.5, 18.3) †74.9 (70.9, 78.9) †51.2 (50.0, 52.5) †21.0 (12.8, 32.8)
Liang et al. 2020 †82.2 (80.3, 84.6) †04.1 (03.6, 05.2) †02.1 (01.0, 03.3) †02.8 (01.3, 04.4) †88.7 (88.0, 89.5) †00.4 (00.3, 00.6)
SOFA †90.2 (88.7, 91.6) †48.1 (43.5, 52.3) †48.8 (45.5, 51.8) †77.3 (73.1, 81.3) †90.2 (89.5, 90.8) †00.0 (00.0, 71.8)
Yan et al. 2020 †82.2 (80.2, 83.9) †54.0 (51.4, 55.9) †38.8 (36.1, 41.3) †81.4 (77.6, 84.8) †83.2 (82.2, 84.0) †00.0 (00.0, 00.0)
4
h
o
u
r
s
CovEWS 96.7 (96.1, 97.2) 65.8 (60.7, 70.6) 55.0 (51.6, 58.1) 91.8 (89.2, 94.6) 89.9 (89.2, 90.7) 86.6 (82.7, 89.0)
CovEWS (linear) †96.5 (95.8, 97.1) 68.6 (63.5, 72.4) †50.9 (48.1, 53.7) 91.8 (89.0, 94.1) †88.4 (87.7, 89.2) †84.1 (81.3, 87.5)
COVER F †65.2 (62.7, 67.7) †08.8 (07.8, 09.7) †16.8 (15.4, 18.3) †74.8 (70.8, 78.8) †51.2 (50.0, 52.5) †21.0 (12.8, 32.8)
Liang et al. 2020 †82.3 (80.7, 84.7) †03.9 (03.5, 04.5) †02.1 (01.0, 03.1) †03.3 (01.5, 05.0) †84.8 (83.9, 85.7) †00.4 (00.3, 00.7)
SOFA †89.9 (88.3, 91.2) †47.0 (42.5, 51.0) †48.2 (44.7, 51.1) †76.0 (72.3, 80.0) 90.2 (89.5, 90.8) †00.0 (00.0, 00.0)
Yan et al. 2020 †82.8 (80.7, 84.4) †54.5 (52.0, 56.5) †39.1 (36.5, 41.7) †82.4 (78.7, 85.9) †83.2 (82.2, 84.0) †00.0 (00.0, 00.0)
8
h
o
u
r
s
CovEWS 96.5 (95.9, 97.1) 63.5 (58.4, 68.3) 52.4 (49.1, 55.6) 91.5 (88.7, 94.2) 89.0 (88.3, 89.7) 85.1 (82.3, 88.0)
CovEWS (linear) †96.1 (95.3, 96.6) 66.1 (61.1, 70.0) †50.1 (47.0, 53.1) †90.3 (87.6, 92.9) †88.4 (87.7, 89.2) †82.9 (79.6, 86.0)
COVER F †65.2 (62.6, 67.5) †08.7 (07.7, 09.6) †16.6 (15.1, 18.0) †74.5 (70.3, 78.5) †51.2 (50.0, 52.5) †21.0 (12.8, 32.8)
Liang et al. 2020 †82.4 (80.3, 84.6) †03.9 (03.5, 04.5) †02.1 (01.1, 03.1) †03.4 (01.7, 04.9) †84.8 (83.9, 85.7) †00.4 (00.3, 00.6)
SOFA †89.8 (88.2, 91.1) †45.8 (41.6, 50.0) †48.2 (45.0, 50.9) †76.2 (72.3, 79.8) 90.2 (89.5, 90.8) †00.0 (00.0, 00.0)
Yan et al. 2020 †82.7 (80.9, 84.6) †54.4 (52.1, 56.4) †38.9 (36.5, 41.4) †82.5 (78.9, 86.0) †83.2 (82.2, 84.0) †00.0 (00.0, 00.0)
1
6
h
o
u
r
s
CovEWS 95.7 (95.0, 96.5) 64.1 (59.1, 69.3) 53.4 (50.0, 56.2) 91.1 (88.5, 93.7) 86.7 (85.8, 87.7) 82.0 (78.7, 85.6)
CovEWS (linear) †94.5 (93.6, 95.3) 64.6 (60.3, 68.4) †52.4 (49.4, 55.0) †84.7 (81.6, 88.1) 88.0 (87.1, 88.9) †74.5 (70.5, 79.3)
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Table S14 cont.
COVER F †63.7 (61.1, 66.3) †10.4 (09.4, 11.7) †19.1 (17.3, 20.8) †69.3 (64.2, 73.5) †52.3 (51.0, 53.8) †18.9 (11.4, 30.3)
Liang et al. 2020 †81.1 (79.0, 83.2) †05.0 (04.4, 06.0) †02.5 (01.2, 03.7) †03.5 (01.7, 05.0) †84.9 (84.0, 85.8) †00.5 (00.3, 00.7)
SOFA †87.2 (85.4, 88.9) †43.6 (39.4, 47.6) †47.0 (43.9, 49.5) †72.6 (68.3, 75.9) 88.0 (87.2, 88.9) †00.0 (00.0, 00.0)
Yan et al. 2020 †81.0 (79.0, 83.0) †55.0 (53.0, 57.2) †39.7 (37.3, 42.3) †82.6 (78.6, 86.5) †79.4 (78.2, 80.3) †00.0 (00.0, 00.0)
2
4
h
o
u
r
s
CovEWS 95.2 (94.3, 95.9) 63.7 (59.1, 68.9) 51.4 (48.2, 54.4) 90.9 (88.1, 93.5) 85.6 (84.5, 86.6) 79.3 (74.9, 83.3)
CovEWS (linear) †94.0 (92.9, 94.9) 64.1 (58.8, 67.8) 51.6 (48.1, 54.4) †83.8 (80.4, 86.7) 87.8 (86.9, 88.7) †73.6 (68.3, 79.1)
COVER F †63.1 (60.6, 65.8) †10.4 (09.3, 11.7) †18.9 (17.3, 20.5) †68.5 (63.7, 72.6) †51.9 (50.6, 53.4) †18.7 (11.3, 29.7)
Liang et al. 2020 †80.3 (78.0, 82.5) †05.0 (04.5, 05.7) †02.8 (01.3, 04.0) †03.8 (01.8, 05.4) †85.0 (84.1, 85.9) †00.5 (00.3, 00.7)
SOFA †86.6 (84.7, 88.4) †42.9 (38.6, 47.1) †46.3 (42.9, 48.8) †71.8 (67.5, 75.8) 87.7 (86.8, 88.5) †00.0 (00.0, 00.0)
Yan et al. 2020 †80.9 (78.6, 82.7) †55.0 (52.3, 57.0) †39.4 (36.9, 42.0) †82.7 (78.9, 86.2) †79.0 (77.7, 80.0) †00.0 (00.0, 00.0)
4
8
h
o
u
r
s
CovEWS 94.9 (93.9, 95.7) 62.8 (57.7, 68.1) 49.6 (45.9, 52.5) 92.2 (89.4, 94.9) 84.1 (82.9, 85.4) 77.8 (70.7, 84.0)
CovEWS (linear) †93.2 (92.0, 94.3) †62.0 (56.7, 65.7) †47.2 (44.0, 50.1) †87.0 (84.2, 90.0) 84.0 (82.9, 85.1) †70.8 (63.5, 76.1)
COVER F †62.8 (60.1, 65.5) †10.2 (09.1, 11.4) †19.0 (17.1, 20.6) †68.8 (64.2, 73.3) †51.3 (49.7, 52.9) †18.4 (11.3, 28.2)
Liang et al. 2020 †79.9 (77.6, 82.4) †05.0 (04.5, 05.8) †02.3 (01.0, 03.7) †03.0 (01.4, 04.8) 86.3 (85.4, 87.3) †00.4 (00.2, 00.6)
SOFA †86.6 (84.9, 88.4) †42.1 (37.7, 46.8) †45.4 (42.0, 48.3) †71.2 (66.8, 75.2) 87.4 (86.4, 88.1) †00.0 (00.0, 00.0)
Yan et al. 2020 †80.2 (78.2, 82.0) †54.3 (52.0, 56.5) †38.2 (35.5, 40.7) †82.3 (78.3, 86.2) †78.0 (76.8, 79.0) †00.0 (00.0, 00.0)
9
6
h
o
u
r
s
CovEWS 93.7 (92.4, 94.8) 57.5 (51.2, 63.5) 48.2 (44.7, 51.7) 87.3 (83.6, 90.9) 85.1 (83.9, 86.3) 74.1 (65.0, 81.1)
CovEWS (linear) †91.7 (90.2, 92.9) 57.1 (51.5, 62.0) †42.1 (38.3, 45.1) †83.7 (80.0, 87.1) †82.6 (81.3, 83.8) †66.7 (56.9, 73.6)
COVER F †62.1 (59.3, 64.9) †09.7 (08.6, 11.1) †18.0 (16.1, 19.6) †68.3 (63.6, 72.8) †50.4 (48.8, 52.1) †16.7 (10.3, 28.1)
Liang et al. 2020 †79.6 (77.4, 81.9) †04.6 (04.1, 05.6) †02.1 (00.6, 03.6) †02.0 (00.6, 03.6) 92.2 (91.4, 92.9) †00.5 (00.3, 00.8)
SOFA †84.9 (82.5, 87.1) †37.6 (32.4, 42.4) †41.4 (37.6, 44.5) †66.8 (62.5, 71.5) 86.8 (85.8, 87.8) †00.0 (00.0, 00.0)
Yan et al. 2020 †79.7 (77.1, 81.7) †53.2 (50.6, 55.8) †36.8 (34.0, 39.8) †81.5 (76.7, 85.4) †77.9 (76.5, 79.0) †00.0 (00.0, 00.0)
1
9
2
h
o
u
r
s
CovEWS 92.2 (90.5, 93.7) 50.6 (43.5, 57.7) 42.2 (37.9, 45.9) 84.6 (79.8, 89.5) 84.7 (83.5, 85.8) 62.8 (56.3, 75.5)
CovEWS (linear) †90.3 (88.1, 92.0) 51.2 (44.2, 56.9) †35.8 (32.0, 39.1) †84.0 (78.9, 87.6) †79.6 (78.3, 81.0) †61.7 (53.6, 69.2)
COVER F †62.1 (58.7, 65.6) †08.2 (07.1, 09.6) †15.9 (14.2, 18.1) †69.7 (63.5, 75.1) †50.5 (48.8, 52.3) †12.5 (09.9, 28.7)
Liang et al. 2020 †76.1 (73.3, 79.2) †04.0 (03.4, 05.4) †02.3 (00.8, 04.4) †02.5 (00.8, 04.6) 92.4 (91.5, 93.2) †00.4 (00.2, 00.6)
SOFA †83.3 (80.5, 85.7) †29.7 (25.0, 35.4) †35.5 (31.4, 39.0) †64.3 (58.8, 70.6) 86.5 (85.4, 87.4) †00.0 (00.0, 00.0)
Yan et al. 2020 †78.1 (75.6, 80.7) 49.8 (47.1, 52.5) †32.2 (28.3, 35.4) †77.9 (72.9, 83.0) †78.3 (77.0, 79.5) †00.0 (00.0, 00.0)
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Table S15: Comparison of CovEWS, CovEWS (linear), COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18] at
various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity and specificity at greater than 95% sensitivity
(Spec.@95%Sens.) for predicting COVID-19 related mortality on the Optum future cohort. Values are the median and the 95%
confidence intervals (CIs, in parentheses) obtained via bootstrap resampling with 200 samples. †= significant at p < 0.05 to
CovEWS (one-sided Mann-Whitney-Wilcoxon, Bonferroni corrected). Best results for each metric are highlighted in bold.
Optum Future Cohort (June 6th to July 13th 2020)
Model AUC AUPR F1 Sensitivity Specificity Spec.@95%Sens.
1
h
o
u
r
CovEWS 97.7 (97.1, 98.3) 27.3 (21.8, 32.7) 22.1 (18.5, 25.4) 90.2 (84.7, 95.9) 95.0 (94.6, 95.3) 90.8 (87.6, 95.5)
CovEWS (linear) 97.8 (96.6, 98.6) 52.5 (42.5, 61.2) 25.0 (21.1, 29.3) †88.4 (81.4, 94.5) 95.8 (95.5, 96.1) †89.3 (81.6, 95.1)
COVER F †88.2 (85.2, 90.8) †06.0 (03.9, 09.7) †05.7 (04.8, 06.6) †88.6 (82.5, 94.5) †76.3 (75.7, 76.9) †54.1 (45.4, 74.0)
Liang et al. 2020 †90.7 (87.0, 93.8) †14.3 (09.9, 20.9) †09.5 (07.9, 11.2) †86.8 (80.2, 92.9) †86.7 (86.1, 87.2) †53.5 (14.5, 70.8)
SOFA †91.5 (88.8, 93.8) †15.9 (10.8, 22.3) †12.3 (10.2, 14.3) †83.0 (76.2, 89.5) †90.6 (90.1, 91.1) †00.0 (00.0, 71.6)
Yan et al. 2020 †88.4 (84.8, 91.8) 46.9 (42.9, 50.4) †11.6 (09.7, 13.6) †87.5 (80.4, 94.3) †89.3 (88.9, 89.7) †00.0 (00.0, 00.0)
2
h
o
u
r
s
CovEWS 97.7 (97.1, 98.2) 26.0 (20.8, 31.7) 22.1 (18.5, 25.4) 90.2 (84.7, 95.9) 95.0 (94.6, 95.3) 90.4 (87.3, 95.7)
CovEWS (linear) 97.7 (96.6, 98.6) 48.7 (38.3, 57.8) 22.5 (18.9, 25.9) 89.4 (82.8, 95.3) 95.1 (94.8, 95.5) †89.3 (82.4, 95.1)
COVER F †88.2 (85.2, 90.8) †06.0 (03.9, 09.7) †05.7 (04.8, 06.6) †88.6 (82.5, 94.5) †76.3 (75.7, 76.9) †54.1 (45.4, 74.0)
Liang et al. 2020 †90.8 (86.8, 93.8) †13.9 (09.6, 20.0) †09.5 (07.9, 11.2) †86.8 (80.2, 92.9) †86.7 (86.1, 87.2) †52.6 (14.4, 77.5)
SOFA †91.2 (88.2, 93.4) †15.4 (10.3, 21.9) †11.9 (09.8, 14.0) †81.0 (73.3, 87.2) †90.6 (90.1, 91.1) †00.0 (00.0, 71.6)
Yan et al. 2020 †88.0 (84.0, 91.3) 46.4 (42.2, 49.9) †11.5 (09.6, 13.5) †86.7 (78.8, 93.3) †89.3 (88.9, 89.7) †00.0 (00.0, 00.0)
4
h
o
u
r
s
CovEWS 97.7 (97.1, 98.2) 25.9 (20.7, 32.1) 20.8 (17.2, 24.0) 89.0 (83.0, 94.3) 94.6 (94.3, 95.0) 90.7 (88.2, 94.7)
CovEWS (linear) 97.8 (96.8, 98.5) 48.6 (36.9, 57.7) 22.1 (18.4, 25.6) 88.3 (81.3, 94.4) 95.1 (94.8, 95.5) †90.4 (82.4, 94.9)
COVER F †88.2 (85.2, 90.8) †06.0 (03.9, 09.7) †05.6 (04.7, 06.5) 88.6 (82.5, 94.5) †76.3 (75.7, 76.9) †54.1 (45.3, 74.0)
Liang et al. 2020 †91.3 (87.2, 94.1) †14.3 (09.7, 20.9) †09.5 (08.0, 11.3) 88.4 (82.1, 94.2) †86.7 (86.1, 87.2) †53.2 (14.3, 85.0)
SOFA †91.2 (88.1, 93.4) †14.8 (09.6, 20.6) †11.8 (09.8, 13.8) †80.4 (72.9, 87.0) †90.6 (90.1, 91.1) †00.0 (00.0, 71.6)
Yan et al. 2020 †88.0 (84.0, 91.3) 46.2 (42.0, 49.9) †11.3 (09.3, 13.5) †86.4 (78.8, 93.3) †89.3 (88.9, 89.7) †00.0 (00.0, 00.0)
8
h
o
u
r
s
CovEWS 97.5 (96.8, 98.1) 23.8 (18.9, 28.9) 19.8 (16.6, 23.0) 91.7 (86.7, 96.3) 94.2 (93.8, 94.6) 90.3 (87.3, 95.1)
CovEWS (linear) †97.1 (95.4, 98.4) 45.6 (35.0, 55.3) 21.6 (18.2, 24.6) †87.2 (80.0, 93.8) 95.1 (94.8, 95.5) †85.2 (76.6, 93.3)
Liang et al. 2020 †92.0 (88.8, 94.5) †12.4 (08.7, 16.4) †09.5 (07.9, 11.2) †88.9 (83.1, 95.1) †86.7 (86.1, 87.2) †60.7 (32.9, 86.8)
COVER F †88.7 (86.0, 91.3) †06.1 (03.9, 09.9) †05.6 (04.8, 06.5) †90.2 (83.2, 95.4) †76.3 (75.7, 76.9) †59.4 (45.5, 76.1)
SOFA †90.5 (87.6, 93.0) †13.3 (08.4, 18.8) †11.2 (09.1, 13.1) †77.3 (69.2, 84.6) †90.6 (90.1, 91.1) †00.0 (00.0, 71.6)
Yan et al. 2020 †87.8 (83.9, 91.2) 46.1 (42.0, 49.8) †11.2 (09.3, 13.2) †86.2 (78.6, 93.2) †89.3 (88.9, 89.7) †00.0 (00.0, 00.0)
1
6
h
o
u
r
s
CovEWS 95.8 (94.5, 97.0) 25.1 (19.3, 31.0) 22.4 (18.9, 25.6) 89.6 (83.5, 95.3) 90.8 (90.1, 91.5) 81.6 (67.0, 92.1)
CovEWS (linear) †95.2 (93.5, 96.9) 39.8 (29.9, 49.0) 25.2 (21.1, 28.8) †84.3 (77.8, 92.3) 92.6 (92.1, 93.2) †69.2 (51.3, 88.7)
Liang et al. 2020 †88.9 (85.5, 92.0) †13.4 (09.4, 17.5) †12.7 (10.6, 15.0) †87.0 (80.5, 93.7) †82.1 (81.2, 83.0) †52.6 (27.8, 79.9)
54
S
ep
tem
b
er
1,
2020
Table S15 cont.
COVER F †84.6 (81.4, 87.7) †06.2 (04.6, 07.9) †09.0 (07.4, 10.5) †79.6 (71.3, 86.8) †76.1 (75.1, 77.2) †50.0 (35.7, 68.0)
SOFA †87.5 (84.1, 90.1) †13.3 (08.7, 18.5) †13.1 (10.7, 15.5) †74.1 (64.9, 82.5) †85.6 (84.8, 86.4) †00.0 (00.0, 66.2)
Yan et al. 2020 †83.5 (79.8, 87.5) 45.6 (41.4, 49.9) †12.8 (10.5, 15.4) †84.0 (76.1, 92.2) †83.0 (82.2, 83.8) †00.0 (00.0, 00.0)
2
4
h
o
u
r
s
CovEWS 95.6 (94.1, 96.9) 23.9 (18.5, 29.0) 22.3 (18.9, 25.8) 91.4 (85.7, 96.5) 90.0 (89.3, 90.7) 83.2 (59.2, 92.2)
CovEWS (linear) †95.1 (93.2, 97.0) 39.2 (28.8, 48.6) 25.1 (20.6, 29.0) †85.7 (78.9, 92.9) 92.1 (91.5, 92.7) †82.6 (40.1, 87.7)
COVER F †85.4 (82.8, 87.8) †06.4 (04.8, 08.2) †09.3 (07.5, 10.8) †81.1 (72.3, 87.8) †75.2 (74.2, 76.3) †57.3 (45.9, 67.7)
Liang et al. 2020 †88.7 (86.0, 91.4) †13.7 (09.9, 18.1) †14.7 (12.3, 17.2) †83.9 (76.4, 90.4) †84.8 (83.9, 85.6) †51.3 (29.1, 77.6)
SOFA †87.1 (83.7, 89.8) †13.5 (08.9, 19.1) †13.2 (10.8, 15.8) †73.6 (64.9, 82.1) †85.1 (84.3, 85.9) †00.0 (00.0, 65.6)
Yan et al. 2020 †83.4 (79.9, 87.3) 46.0 (42.0, 50.2) †13.0 (10.8, 15.7) †84.4 (77.7, 92.4) †82.4 (81.6, 83.3) †00.0 (00.0, 00.0)
4
8
h
o
u
r
s
CovEWS 94.2 (92.5, 95.7) 21.5 (16.4, 26.7) 20.3 (16.5, 23.2) 84.7 (77.1, 91.7) 88.6 (87.8, 89.5) 78.6 (62.8, 83.2)
CovEWS (linear) †93.7 (91.8, 95.6) 36.6 (26.4, 45.6) 21.9 (18.2, 24.8) 83.8 (76.6, 91.0) 89.8 (89.1, 90.6) †65.0 (48.5, 82.3)
COVER F †84.4 (81.4, 87.0) †06.5 (04.9, 08.5) †09.3 (07.6, 10.9) †79.6 (71.5, 87.4) †73.3 (72.2, 74.6) †55.8 (44.5, 65.0)
Liang et al. 2020 †88.3 (84.7, 90.9) †14.8 (10.6, 20.4) †15.2 (12.7, 17.9) †81.7 (74.4, 87.7) †84.5 (83.6, 85.4) †46.4 (31.2, 66.5)
SOFA †85.7 (82.0, 88.4) †13.2 (09.3, 19.0) †13.3 (10.8, 16.0) †72.7 (63.6, 81.5) †84.0 (83.2, 84.8) †00.0 (00.0, 64.3)
Yan et al. 2020 †81.9 (78.3, 86.0) 45.1 (40.9, 49.4) †13.0 (10.5, 15.3) †82.8 (74.8, 91.0) †81.0 (80.1, 82.0) †00.0 (00.0, 00.0)
9
6
h
o
u
r
s
CovEWS 91.7 (88.5, 93.6) 17.7 (12.7, 23.4) 20.1 (15.9, 23.3) 76.5 (67.6, 84.3) 88.5 (87.8, 89.4) 71.5 (58.2, 78.0)
CovEWS (linear) 91.7 (88.6, 94.4) 27.9 (18.1, 38.1) 20.1 (16.5, 24.1) 83.5 (75.0, 90.4) †87.5 (86.7, 88.5) †60.9 (48.0, 79.5)
COVER F †82.8 (79.4, 85.6) †06.0 (04.6, 08.0) †09.6 (07.7, 11.7) 81.0 (72.3, 88.9) †70.8 (69.3, 72.2) †54.6 (42.3, 62.6)
Liang et al. 2020 †86.6 (82.5, 89.6) †12.7 (08.2, 18.7) †15.2 (12.1, 17.7) 81.5 (72.1, 89.1) †82.6 (81.3, 83.7) †43.6 (25.6, 73.7)
SOFA †82.2 (77.6, 86.3) †12.0 (07.8, 17.0) †13.6 (10.5, 16.4) †70.1 (60.4, 79.8) †83.3 (82.3, 84.3) †00.0 (00.0, 00.0)
Yan et al. 2020 †81.0 (76.4, 84.9) 44.8 (40.0, 49.0) †13.6 (11.0, 16.2) 82.0 (72.8, 89.6) †80.1 (79.0, 81.3) †00.0 (00.0, 00.0)
1
9
2
h
o
u
r
s
CovEWS 90.4 (86.4, 93.8) 17.7 (11.3, 24.9) 19.5 (14.9, 24.6) 78.0 (66.6, 88.0) 87.6 (86.3, 88.8) 70.8 (01.2, 81.3)
CovEWS (linear) 90.1 (86.0, 93.8) 29.6 (17.9, 41.9) †17.8 (13.5, 22.3) 79.8 (66.7, 87.7) †85.7 (84.4, 86.9) †66.0 (00.0, 77.7)
COVER F †80.9 (76.8, 84.5) †05.5 (03.6, 07.6) †09.6 (07.1, 12.0) †72.4 (60.0, 82.9) †73.4 (71.8, 75.0) †53.6 (39.6, 60.1)
Liang et al. 2020 †84.9 (80.8, 89.3) †12.6 (07.7, 21.8) †12.6 (09.6, 15.6) 82.9 (73.1, 92.2) †77.3 (75.8, 78.9) †48.5 (24.3, 67.0)
SOFA †79.0 (73.2, 85.1) †12.1 (07.0, 19.6) †13.2 (10.3, 17.2) †68.1 (57.6, 79.3) †83.0 (81.5, 84.3) †00.0 (00.0, 00.0)
Yan et al. 2020 †81.2 (75.6, 85.8) 44.8 (38.8, 50.0) †14.4 (10.7, 18.0) 81.1 (70.3, 90.6) †81.0 (79.5, 82.3) †00.0 (00.0, 00.0)
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Table S16: Comparison of CovEWS, CovEWS (linear), COVER F [19], SOFA [14], Yan et al. [17], and Liang et al. [18] at
various prediction horizons in terms of AUC, AUPR, F1, sensitivity, specificity and specificity at greater than 95% sensitivity
(Spec.@95%Sens.) for predicting COVID-19 related mortality on the subgroup of non-hospitalised patients of the Optum test
set. Values are the median and the 95% confidence intervals (CIs, in parentheses) obtained via bootstrap resampling with 200
samples. †= significant at p < 0.05 to CovEWS (one-sided Mann-Whitney-Wilcoxon, Bonferroni corrected). Best results for
each metric are highlighted in bold.
Optum Test Set (Not Hospitalised Subgroup)
Model AUC AUPR F1 Sensitivity Specificity Spec.@95%Sens.
1
h
o
u
r
CovEWS (linear) 96.7 (95.6, 97.5) 50.0 (43.3, 57.3) 40.5 (36.5, 44.1) 85.4 (80.6, 89.3) 93.8 (93.2, 94.3) 86.3 (77.7, 89.6)
CovEWS 96.6 (95.1, 97.6) 49.4 (43.3, 55.8) 42.2 (38.3, 46.6) 86.9 (82.8, 91.0) 94.1 (93.6, 94.6) 85.5 (77.8, 91.2)
Liang et al. 2020 †84.4 (81.6, 86.7) †18.8 (15.2, 23.6) †16.3 (14.2, 18.7) †77.8 (72.3, 82.9) †79.8 (78.8, 80.5) †34.0 (20.9, 45.4)
COVER F †69.8 (66.4, 72.3) †04.4 (03.7, 05.2) †08.2 (07.0, 09.2) †77.0 (70.9, 81.6) †55.5 (54.6, 56.5) †17.8 (14.5, 26.3)
SOFA †91.4 (88.9, 93.1) †28.1 (23.6, 34.0) †29.5 (26.7, 32.7) †81.2 (75.9, 86.1) †90.3 (89.7, 91.0) †00.0 (00.0, 74.5)
Yan et al. 2020 †84.0 (81.3, 85.8) †47.6 (44.6, 50.0) †22.5 (20.2, 25.2) †82.0 (76.8, 86.0) †85.9 (85.0, 86.6) †00.0 (00.0, 00.0)
2
h
o
u
r
s
CovEWS (linear) 96.7 (95.5, 97.5) 49.2 (42.7, 56.4) 36.6 (33.0, 40.2) 86.5 (82.0, 90.3) 92.5 (91.9, 93.0) 86.3 (77.7, 90.7)
CovEWS 96.6 (95.1, 97.6) 49.4 (43.0, 55.5) 42.5 (38.3, 46.7) 87.5 (83.4, 91.4) 94.1 (93.6, 94.6) 85.8 (77.8, 91.2)
Liang et al. 2020 †84.5 (81.7, 86.9) †18.8 (15.2, 23.4) †16.4 (14.4, 18.8) †78.2 (73.0, 83.1) †79.8 (78.8, 80.5) †34.0 (20.9, 45.4)
COVER F †69.8 (66.4, 72.3) †04.4 (03.7, 05.2) †08.2 (07.0, 09.2) †77.0 (70.9, 81.6) †55.5 (54.6, 56.5) †17.8 (14.5, 26.3)
SOFA †91.1 (88.7, 92.8) †27.6 (23.1, 33.5) †29.5 (26.8, 32.7) †81.2 (76.1, 86.1) †90.4 (89.7, 91.0) †00.0 (00.0, 74.4)
Yan et al. 2020 †84.0 (81.3, 85.8) †47.6 (44.6, 50.0) †22.5 (20.2, 25.2) †82.0 (76.8, 86.0) †85.9 (85.0, 86.6) †00.0 (00.0, 00.0)
4
h
o
u
r
s
CovEWS 96.5 (95.1, 97.6) 46.3 (40.4, 52.8) 40.4 (36.5, 44.5) 88.4 (84.3, 92.7) 93.6 (93.0, 94.2) 85.7 (81.9, 90.0)
CovEWS (linear) 96.5 (95.4, 97.4) 48.0 (41.4, 55.2) †36.0 (32.4, 39.9) †85.8 (81.4, 90.0) †92.5 (91.9, 93.0) 85.6 (76.2, 89.1)
Liang et al. 2020 †85.1 (81.9, 87.3) †18.5 (14.8, 23.1) †16.0 (14.1, 18.5) †77.9 (72.4, 82.8) †79.8 (78.8, 80.5) †34.6 (21.9, 46.6)
COVER F †69.9 (66.5, 72.5) †04.4 (03.6, 05.1) †08.1 (06.9, 09.1) †76.9 (71.1, 81.7) †55.5 (54.6, 56.5) †18.1 (14.4, 37.5)
SOFA †90.9 (88.5, 92.7) †26.4 (22.3, 32.4) †28.9 (25.8, 32.0) †80.5 (75.0, 85.6) †90.4 (89.7, 91.0) †00.0 (00.0, 74.4)
Yan et al. 2020 †84.2 (81.7, 86.1) 48.0 (45.1, 50.0) †22.4 (20.0, 25.0) †82.4 (77.9, 86.5) †85.9 (85.0, 86.6) †00.0 (00.0, 00.0)
8
h
o
u
r
s
CovEWS 96.5 (94.9, 97.5) 43.8 (37.7, 50.4) 37.4 (33.5, 40.7) 87.7 (83.3, 92.1) 92.9 (92.3, 93.5) 86.0 (81.9, 91.5)
CovEWS (linear) 96.4 (95.3, 97.3) 44.0 (37.4, 51.3) †36.1 (32.6, 40.0) 87.8 (83.8, 92.1) †92.5 (91.9, 93.0) †84.9 (75.9, 90.1)
Liang et al. 2020 †85.5 (82.3, 87.6) †19.2 (14.9, 24.4) †16.0 (14.2, 18.4) †79.0 (73.7, 84.3) †79.8 (78.8, 80.5) †34.4 (21.7, 54.7)
COVER F †69.7 (66.2, 72.2) †04.2 (03.5, 05.0) †07.8 (06.7, 08.9) †76.2 (70.0, 81.5) †55.5 (54.6, 56.5) †18.0 (14.3, 37.2)
SOFA †90.1 (87.8, 92.1) †25.4 (21.5, 31.5) †27.8 (24.9, 31.1) †78.6 (73.7, 84.1) †90.3 (89.7, 91.0) †00.0 (00.0, 01.8)
Yan et al. 2020 †84.0 (81.5, 85.9) 47.6 (44.8, 49.8) †21.9 (19.5, 24.6) †82.1 (76.8, 85.9) †85.9 (85.0, 86.6) †00.0 (00.0, 00.0)
1
6
h
o
u
r
s
CovEWS 95.3 (93.5, 96.4) 42.1 (36.2, 49.4) 38.1 (34.1, 41.7) 86.7 (81.7, 90.9) 91.2 (90.4, 91.9) 82.5 (73.7, 86.8)
CovEWS (linear) 95.1 (93.7, 96.3) 41.4 (35.4, 48.8) 38.2 (34.2, 42.4) †81.9 (77.3, 86.6) 92.0 (91.3, 92.6) †79.2 (71.6, 86.0)
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Liang et al. 2020 †83.0 (79.8, 85.4) †19.8 (15.2, 25.2) †19.6 (17.2, 22.1) †70.4 (64.3, 76.5) †82.2 (81.1, 83.1) †27.9 (22.4, 42.2)
COVER F †68.3 (64.7, 70.9) †05.2 (04.3, 06.1) †09.6 (08.1, 10.7) †77.1 (71.2, 82.7) †53.1 (52.0, 54.2) †16.8 (03.9, 35.2)
SOFA †87.8 (84.8, 90.0) †23.8 (19.2, 29.4) †27.7 (24.3, 31.1) †75.9 (70.0, 81.5) †88.0 (87.2, 88.8) †00.0 (00.0, 00.0)
Yan et al. 2020 †81.9 (78.9, 84.2) 47.6 (44.1, 50.0) †22.7 (19.8, 25.2) †81.1 (75.5, 86.0) †82.7 (81.6, 83.5) †00.0 (00.0, 00.0)
2
4
h
o
u
r
s
CovEWS 94.3 (92.4, 95.9) 40.4 (34.0, 47.5) 35.0 (31.3, 38.6) 84.9 (80.2, 89.2) 90.1 (89.4, 90.9) 78.6 (57.1, 82.9)
CovEWS (linear) 94.4 (92.8, 95.8) 40.7 (34.6, 48.0) 37.1 (33.2, 41.3) †81.4 (76.4, 86.6) 91.6 (90.9, 92.3) †75.7 (61.3, 83.1)
Liang et al. 2020 †82.4 (78.6, 85.1) †20.6 (15.2, 25.5) †17.5 (15.2, 19.6) †78.0 (71.8, 83.7) †76.3 (75.0, 77.4) †25.2 (08.0, 36.1)
COVER F †68.1 (64.3, 70.8) †05.2 (04.2, 06.1) †09.4 (07.9, 10.6) †76.5 (70.4, 81.9) †52.4 (51.3, 53.5) †16.6 (04.0, 36.2)
SOFA †87.0 (84.4, 89.6) †21.8 (17.8, 27.1) †26.5 (23.4, 30.3) †74.4 (67.6, 81.3) †87.4 (86.7, 88.2) †00.0 (00.0, 00.0)
Yan et al. 2020 †81.6 (78.9, 83.9) 47.4 (44.0, 49.8) †22.1 (19.6, 25.0) †81.2 (76.1, 85.5) †82.0 (80.9, 83.0) †00.0 (00.0, 00.0)
4
8
h
o
u
r
s
CovEWS 93.9 (91.8, 95.5) 38.6 (32.4, 46.3) 34.1 (30.4, 37.5) 86.2 (81.3, 90.9) 89.3 (88.4, 90.2) 77.2 (45.5, 82.5)
CovEWS (linear) †93.6 (91.6, 95.1) 38.6 (31.1, 46.2) †32.7 (28.7, 37.0) †84.3 (79.2, 88.9) †88.9 (88.2, 89.7) †73.0 (59.4, 80.3)
Liang et al. 2020 †81.6 (78.1, 84.4) †17.8 (12.9, 22.2) †16.7 (14.2, 19.2) †78.3 (72.3, 84.2) †74.7 (73.4, 75.8) †21.7 (04.7, 37.7)
COVER F †67.6 (63.7, 70.5) †05.1 (04.2, 06.2) †09.6 (08.1, 11.2) †73.6 (66.3, 79.1) †55.0 (53.7, 56.2) †15.8 (03.1, 34.3)
SOFA †86.7 (84.0, 89.4) †21.4 (17.3, 27.1) †25.2 (21.8, 29.2) †71.5 (64.4, 78.1) †86.9 (86.1, 87.8) †00.0 (00.0, 69.0)
Yan et al. 2020 †81.1 (77.7, 83.5) 47.2 (43.4, 49.6) †21.9 (18.8, 24.5) †80.8 (74.4, 85.6) †81.4 (80.3, 82.4) †00.0 (00.0, 00.0)
9
6
h
o
u
r
s
CovEWS (linear) 93.1 (91.0, 94.6) 35.8 (29.8, 44.5) 27.8 (24.1, 31.9) 81.4 (75.5, 86.9) 88.0 (87.3, 88.8) 72.6 (58.5, 80.1)
CovEWS 93.1 (90.9, 94.9) 34.3 (28.4, 42.6) 30.2 (26.6, 34.6) 81.7 (74.3, 87.0) 89.4 (88.6, 90.2) 71.6 (54.8, 81.0)
Liang et al. 2020 †78.1 (73.6, 82.0) †13.8 (09.5, 18.7) †14.4 (11.9, 17.1) †73.0 (65.7, 79.4) †74.8 (73.5, 76.1) †14.2 (02.2, 35.0)
COVER F †66.3 (61.1, 69.6) †04.4 (03.5, 05.4) †08.3 (06.7, 09.6) †75.4 (68.2, 81.1) †51.2 (49.9, 52.5) †14.0 (02.9, 32.7)
SOFA †85.3 (82.2, 88.3) †17.7 (14.1, 23.1) †23.3 (20.0, 27.0) †72.9 (66.3, 80.5) †86.5 (85.6, 87.4) †00.0 (00.0, 00.0)
Yan et al. 2020 †78.7 (75.1, 81.3) 43.7 (39.4, 46.8) †18.9 (16.1, 21.9) †75.9 (68.4, 81.5) †81.4 (80.2, 82.4) †00.0 (00.0, 00.0)
1
9
2
h
o
u
r
s
CovEWS 92.9 (90.8, 94.7) 28.6 (20.7, 38.7) 26.0 (20.8, 30.5) 78.2 (68.8, 85.4) 89.8 (88.9, 90.8) 71.2 (56.4, 81.9)
CovEWS (linear) †91.7 (89.3, 93.9) †27.0 (21.2, 37.6) †20.8 (17.0, 25.5) 77.8 (69.1, 86.5) †86.4 (85.5, 87.4) 70.6 (42.7, 76.4)
COVER F †65.5 (60.1, 69.7) †03.4 (02.4, 04.5) †06.6 (04.9, 08.1) †73.2 (63.6, 81.2) †50.9 (49.4, 52.6) †18.3 (11.3, 33.4)
Liang et al. 2020 †73.6 (67.7, 78.5) †11.3 (06.4, 16.9) †09.9 (07.7, 11.9) †70.2 (61.8, 79.4) †70.0 (68.5, 71.6) †05.8 (00.0, 30.3)
SOFA †84.5 (80.8, 88.0) †13.3 (09.4, 19.8) †18.0 (14.4, 22.1) †68.2 (58.3, 78.1) †86.1 (85.1, 87.2) †00.0 (00.0, 00.0)
Yan et al. 2020 †76.8 (72.3, 81.2) 40.2 (35.7, 45.4) †15.7 (12.6, 19.0) †71.1 (62.4, 80.0) †82.4 (81.3, 83.5) †00.0 (00.0, 00.0)
57
S
ep
tem
b
er
1,
2020
